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KARYOTYPING IN CHRONIC MYELOID LEUKEMIA 
 
 
ABSTRACT 
 
 The prognostic relevance of additional cytogenetic findings at diagnosis 
of Chronic Myeloid Leukemia (CML) is unclear. The impact of additional 
cytogenetic findings at diagnosis on time to progression free survival and 
clinical and laboratory features along with disease course is analysed in 30 cases 
of Chronic Myeloid Leukemia and compared with patients presenting with 
standard t(9,22)(q34,q11.2) only karyotype. 6 cases (20%) were found to have 
abnormal karyotype at diagnosis, of which 4(13.33%) were additional 
chromosomal abnormality(ACA), 1 patient (3.33%) had complex variant 
karyotype and 1 patient (3.33%) had –Y. On median observation for 15 months, 
the patients with ACA were found to have accelelaration of disease, abnormally 
high counts, renal compromise and unexplained thrombocytopenia  and this 
indeed signifies the importance of cytogenetic diagnosis at initial diagnostic 
workup and the impact they have on progression of disease and prognosis. 
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INTRODUCTION 
 
 The pluripotent hematopoietic stem cells give rise to Chronic 
myelogenous Leukemia. The disease arises as a clonal process. The 
disease symptoms are anemia, increased production of myeloid 
precursors with maturation and splenic enlargement in varying degrees. 
Among all leukemia cases CML constitutes 20%. More often affected are 
males when compared to females and the ratio is approximately 3:2. The 
age range of 40 - 60 years is the age range with greatest incidence.  
 
 Chronic Myeloid Leukemia is characterised by rearrangement due 
to translocation between  chromosome 9 long arm and chromosome 22 
long arm and this fusion produces a fusion product, BCR-ABL gene, a 
230KD protein, which pathogenetically has increased tyrosine kinase 
activity and marks the disease process.1   
 
 The genotypic defect in CML can be detected over the 
chromosomes which shows translocation or the fusion gene, bcr – abl 
protein or the chimeric RNA or the protein product that gets altered. The 
standard investigation for diagnosis of CML is still cytogenetics1 even 
though many latest genomic sequence detection methods are available.  
The major advantage of Karyotypic analysis compared to Flourescent In 
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Situ Hybridization and Reverse Transcriptase-PCR is the possibility of 
detecting chromosomal aberrations other than the standard t(9,22) 
Philadelphia such as major and minor route additional chromosomal 
abnormalities and variant translocations that may have impact on 
prognosis.1 
 
 Cytogenetic studies reveal the Philadelphia chromosome which 
corresponds to translocation between chromosome 9 and 22, is seen in 
90-95% of CML, whereby  chromosome 22 appears to be ‘shortened’. 
Reciprocal translocation t(9;22)(q34.1;q11.2) whose product is standard 
Philadelphia constitutes more than 90% of the Ph translocation. Variant 
translocations is seen in remaining 5 -10% patients which may be 
complex type or simple type. High-resolution banding studies show 
cryptical involvement of translocation of 9q34 to 22q11 in simple and 
complex variant translocation. Additional  chromosomal aberrations or 
ACA occurring with disease progression is estimated to be 75-80%. In 
few cases, ACA can occur even at the intial disease course itself and if at 
all they are diagnosed at the beginning, the worse course they impart 
could be missed and appropriate management measures could not be 
taken. The presence of ACA at disease onset signifies a poor prognosis.3                 
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REVIEW OF LITERATURE 
 
 In the era of twentieth century, the classic myeloproliferative 
disorders (MPDs) like, primary myelofibrosis (PMF), chronic 
myelogenous leukemia (CML), essential thrombocythemia and 
polycythemia vera were described.4,5,6,7,8,9 These four pathologic entities 
were classified by William Dameshek, along with others in 1951 as 
'MPDs'.10  The MPDs history even antedates Dameshek by a century or 
more and from his time many developments are made in discovering the 
disease process, including BCR–ABL11,12,13,14 and  JAK2V617F.15,16,17,18,19 
 
 Van Leeuwenhoek made the definition of the red blood cell and 
William Hewson (1739–1774) English physicians, the white blood cells 
and he is known as 'Father of Hematology'.14,15 
 
 In 1845, English pathologist John Hughes Bennett (1812–1875), 
reported the first case of Chronic Myeloid Leukemia titled “Case of 
hypertrophy of the spleen and liver in which death took place from 
suppuration of the blood”.16  
 
 It was Virchow in 1847 who named the new entity as 'Leukhemia', 
while Bennet said its 'Leucocythaemia' . Despite controversy, Virchow 
ceded priority to Bennett ultimately. 
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 Difference between granulocytic  and lymphatic variants of 
Leukemia were described by Virchow. In 1868, a German pathologist, 
Ernst Christian Neumann, putforth the theory of formation of blood cells  
from marrow of bone24. Leukemias were later classified into myeloid and 
lymphoid subtypes in 1880 by Paul Ehrlich who described the concept of 
common stem cell & it’s progeny into distinct cell lineages.25 
 
 William Dameshek, a Russian by birth, along with Henry M 
Stratton, introduced BLOOD – which is the The Journal of Hematology. 
He was then given the first post in the journal as the editor-in-chief.27 
BLOOD became the official ASH publication in 1976. His most 
important contribution was the creation of American Society of 
Hematology and International Society of Hematology in 1958 and 1946 
respectively. William Dameshek held the post of the President of above 
said groups in 1964 and 1956, respectively.28  
 
THE PHILADELPHIA CHROMOSOME DISCOVERY: 1960 
 Unexpectedly one day while working at the Pennsylvania 
University, Peter Nowell (1928), an biologist in tumor, noticed in 
Leukemia cases that the chomosomes at metaphases are visualized in cell 
culture slides29, and in the same year Nowell with David Hungerford 
discovered Y Chromosomes. Chromosome spreading using hypotonic 
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solutions were discovered in 1953.30 In 196031, the discovery of Nowell 
was published.  
 
 Nowell also established the specific chromosomal abnormality in 
classical 7 cases of CML.32 This historic discovery followed the 
discovery of the specific chromosomal abnormality and finally the 
invention of the human chromosomes as diploid with 46 chromosomes in 
195633. This was followed by discovery of constitutional chromosomal 
abnormalities in 195934. In CML, abnormally small chromosomes are 
discovered which are found to be directly disease related. 
 
 This chromosome in CML which was abnormal was termed as the 
Philadelphia chromosome (Ph1) in 1960 where, for the first time, the 
international conference on Chromosomal Nomenclature was held. The 
concept that acquired chromosomal aberrations34 are the cause for cancers 
was developed based on discovery of Ph chromosome.  
 
CYTOGENETICS OF THE PH CHROMOSOME: 1973 
 In 1970, the techniques of chromosome banding using Giemsa and 
quinacrine methods by Caspersson and colleagues helped identify the 
Philadelphia chromosome.35 The reciprocal translocation of Philadelphia 
chromosomes 9 and 22; involving the locus 34 and 11 was discovered as 
t(9;22)(q34;q11) by Janet Rowely in 1972.36 
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MOLECULAR DESCRIPTION OF BCR–ABL: 1982 TO 1990 
 ABL gene is mapped to chr-9 and is found to be 225 kb gene, 
which was discovered in 1982. In 1984, the same persons who discovered 
chromosomes also pointed out the breakpoint on chromosome 22 which 
is mapped to 5.8 kb area on long arm (q) of the chromosome which is 
termed as breakpoint cluster region and this breakpoint is found to be 
located in the 135 kb BCR gene.37 Also 8.5 kb on chromosome 22 is 
termed as BCR-ABL fusion product in 1985 [38][39][40][41] that corresponds 
to 210 KD protein.42 Later in 1986 & 1987, similar fusion was described 
in acute lymphoblastic leukemia with 190 KD protein product.43   210 KD 
protein was found to cause CML like disease in mice44 and thus became 
the disease causing mutation in CML. 
 
TARGETING LEUKEMIC STEM CELLS BY BREAKING THEIR 
DORMANCY: 
 Only a few population of tumor cells can form new tumors when 
they are transplanted to new host. This hierarchical organization of tumor 
cells is similar to self-renewing tissue and these cells which are termed 
tumor initiating cells or cancer stem cells (CSCs), that can give rise to 
new tumor and this hypothesis is first discovered in mice.45 Like normal 
Hematopoeitic stem cells cancer stem cells show the same CD34+ CD38-  
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cell surface phenotype and their transplantation does not lead to 
proliferation of leukemia progeny.48 In AML this initial observation was 
made and this same hierarchical organization was found in many 
leukemias. Like CML, many more solid cancers like breast, colon, 
prostate and brain tumors have this hierarchial organisation47. Based on 
different types of tumors, varying stages of the disease and individual 
parameters, the quantity of cancer stemcells vary. Cancer stem cells are 
very rare, in few tumors amounting to < 1 in 10 X 109 or < 1 in 100 X 109 
cells, while in few malignancies, many cancer stem cells have tumor 
initializing capacity. Recent studies show that even differentiated tumor 
cells, either + or CD34-show tumor initiating properties as the nature of 
tumor becomes malignant49.  
 
 The property of quiescence, high resistance to radiotherapy, DNA 
damage and repair mechanism and increased tolerance to anti-
proliferative chemotherapy are seen in CSC as like normal stem cells. 
Because of the above said properties, CSC easily survive and they cannot 
be destroyed easily as like cancer cells in many solid tumors where 
debulking is easy. Tumor relapse and tumor metastasis is due to the 
presence of these residual cancer stem cells even though initial 
chemotherapy successfully destroys the tumor. 
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LEUKEMIA STEM CELLS IN CML: 
 Hierarchically organised leukemic stem cells are seen in CML after 
their initial description in Acute myeloid leukemia. As described 
previously, like normal hematopoietic stem cells, these leukemic stem 
cells in CML also have the same phenotype. But the phenotype of LSC in 
CML is still controversially discussed.  
 
 CML is characterised by overgrowth of bone marrow myeloid 
precursors and maturing series. It was the first malignancy that was 
linked to a specific genetic abnormality, a single chromosomal 
translocation between 9th and 22nd chromosome producing a fusion 
product whose chromosomal event (reciprocal translocation) being 
termed Philadelphia chromosome. Depending on the exact breakpoint the 
size of the resulting fusion protein varies, ranging from 185 to 210kD 
with p210 BCR-ABL being the clinically most important isoform [1]. The 
fusion protein BCR-ABL is the causative and is found to be sufficient for 
driving the development of the disease, and therefore became an ideal 
drug target. Thus came Imatinib mesylate, drug that specifically inhibits 
the BCR-ABL tyrosine kinase, as well as to a lower degree c-kit and 
PDGF-receptor.51 
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STEM CELL CONCEPT OF FORMATION OF CML: 
Below are the evidences for single stem cell origin of CML: 
 
a) Translation of all the myeloid series proliferation like  erythroid, 
neutrophil, eosinophil, basophil, monocytoid and thrombocytoid 
proliferations in CML chronic stage.  
 
b) The Philadelphia (Ph) chromosome could be demonstrated in all 
the above mentioned series53. 
 
c) A single G-6-PD isoenzyme could be demonstrated in all the 
myeloid series and red cells, but this is not seen in other somatic 
cells in patients with CML. 
 
d) The occurence of the Ph translocation in a particular clone only, 
not in all cell lines.  
 
e) The occurence of the Ph chromosome in single cell line only in 
patients who are sex chromosome mosaics. 
 
f) Breakpoint within 5.8kb region of BCR-ABL gene among all cells, 
within a single CML patient, as described by molecular studies. 
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EPIDEMIOLOGY OF CHRONIC MYELOID LEUKEMIA: 
 Worldwide incidence rate of CML varies from as small as <1.0 to 
2.0 per 1 lakh cases / Year, representing 14% of all cases of leukemia. 
Children harbouring CML constitutes about 3%, and in 5–20 years age 
group its 10%.54 Switzerland, USA, Italy, Australia, Germany, and UK 
ranks highest in incidence rates, while Netherlands, Sweden, China, and 
India being the lowest.55 More often affected are males when compared to 
females and the ratio is approximately 3:2.56 
 
CLINICAL FEATURES OF CML: 
 Symptoms pertaining to anaemia, like fatigue, splenic discomfort, 
dyspnoea, weight loss and anoxia due to enlarging spleen are the most 
common symptoms. Neutropenia is absent and thrombocytopenia is not 
seen in chronic phase of disease. Most of the patients present 
asymptomatically, when blood tests are performed for routine check-up. 
Pallor and splenomegaly are the most common sign. 80-90% of cases 
have enlarging spleen. In absence of splenomegaly, a low leucocyte count 
of <100 x 109/l is noted. Increased leucocyte counts of more than 
500000/l may be associated with dilatation of retinal veins. Diagnosis of 
CML can be made by blood counts and by peripheral blood films 
examination. Smear show increased proliferation of granulocytic forms, 
from myeloblasts to neutrophils, with two peaks consisting of mature 
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neutrophils and myelocytes, with few metamyelocytes. Leukocyte counts 
are markedly elevated from 250 x 109/l to even as high as 1000 x 109/ l on 
the time of diagnosis. Progressive rise in counts is seen in untreated 
patients. 
 
 Other findings include, reduced neutrophil alkaline phosphatase 
score, increased serum vitamin B12 levels and vitamin B12 binding 
protein which is transcobalamin 1. But these findings are not significant 
for the disease. 
 
COURSE OF CHRONIC MYELOID LEUKEMIA: 
Chronic myeloid leukemia evolves through three phases. 
• Initial chronic phase 
• Accelerated phase 
• Blast phase 
 
 In the first chronic phase, patient presents with elevated total 
leucocyte count, as much as 80,000 cells/microL to as much as 100,000 
cells . there may be slight reduction in haemoglobin concentration with 
marked elevation in platelet count.  Invariably patients present with 
moderate to massive splenomegaly.57 Patients respond very well to 
imatinib 400mg once daily. More than 90% achieve complete 
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haematological and cytogenetic response in three months of treatment. 
Few untreated or resistant cases or cases with abnormal cytogenetics go 
in for treatment failure and progress to accelerated phase.  
 
 According to revised World Health Organization (WHO) 
classification, evidence of “progressive disease” include features listed 
which are features of accelerated phase:  
 
1) persistent or increasing WBC count of >10 × 109/L with or without 
splenomegaly which is either stable or increasing progressively not 
responding to treatment;  
 
2) persistent of thrombocytosis, with a count of platelet more than 1o 
lakhs/L not responding to treatment. 
 
3) persistent of thrombocytopenia, with counts of platelets of less than 
100 × 109/L not responding to treatment;  
 
4) occurrence of cytogenetic non random chromosomal abnormality 
on progression independent of  diagnostic cytogenetic study;  
 
5) 20% or more basophils counted in blood from periphery 
 
6) blood or marrow myeloblasts of 10 to 19%.58  
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“The WHO criteria for CML-BP include the following:  
1) Blasts equal to or greater than 20% of the peripheral blood 
leukocytes or of the nucleated cells of the bone marrow or  
 
2) An extramedullary proliferation of blasts.”  
 
 Transformation of chronic to either accelerated or blast phase is 
characterised by following additional cytogenetic findings such as extra 
Ph, +8, +19 or isochromosome 17q in most cases.59  
 
LABORATORY FINDINGS IN CML: 
 The peripheral blood complete analysis shows marked leucocytosis 
with median WBC count of > 100,000/µL [100 × 109/L]; with two peaks 
consisting of segmented neutrophils and of myelocytes.60 Less than 2% of 
blasts ae seen, but absolute basophilia imay be present61 in majority of the 
cases. The platelet count ranges from 1.5 to 30 lakhs/µl to more than 
10,00,000 lakhs/L, but presenting with thrombocytopenia are very rare. 
 
BONEMARROW ASPIRATION IN CML: 
 Increased cellularity & increased cellular fragments in marrow 
particles aspirated comprising of granulocytic proliferation together with 
a maturing cell pattern like that in blood and myeloblast count of 5% or 
less of the nucleated cells in the marrow.62 Erythroid colonies are 
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decreased in number.63 Size of the erythroid colonies are also reduced. 
Slightly there occurs mild decrease to marked increase in number of 
megakaryocytes. Megakaryocytes are small in number compared to 
normal and nuclei are hypolobated.  
 
BONEMARROW BIOPSY IN CML: 
 In Bone marrow biopsy, chronic phase of Chronic Myelogenous 
Leukemia before treatment are characterized by a markedly heterogenous 
population demonstrable by trephine biopsies, immunohistochemistry and 
morphometry. Proliferation not only of granulocytic lineage, but also 
megakaryocytes, erythroid precursors, and lymphocytes. Stromal 
components composed of reticulin and collagen fibers has a major role in 
the disease process. Number of megakaryocytes and number of their 
precursors have correlation with fiber density. Thus in pathomechanisms 
of myelofibrosis megakaryopoiesis and fibroblasts have functional 
relationship. In 30% cases, reticulin fibrosis is shown to be moderate to 
marked at diagnosis, demonstrable with reticulin stain in biopsy samples 
and this feature is associated with a poor prognosis in spite of tyrosine 
kinase inhibitors. Also there is correlation between increase in stromal 
component and features like anemia, spleen size percentages of 
myelobasts and erythroblasts in the peripheral blood or LDH level. These 
features are seen in advanced stages of CML which implies a transition to 
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myeloid metaplasia and carry a significant prognostic impact on 
survival.65 
 
SPLEEN AND CML: 
 Splenomegaly is present in invariably all patients with chronic 
myeloid leukemia irrespective of phase of presentation. Size of the spleen 
correlates with prognosis in cml.65 In cases that present with CML blast 
crisis, presence of splenomegaly is an important sign to differentiate these 
patients from denovo AML, ALL from CML myeloid & lymphoid blast 
crisis. 
 
DIAGNOSTIC MOLECULAR MODALITIES IN CML: 
There are 3 phases in study of cytogenetic: 
 
Three phases in Cytogenetics of human cells are: 
i) The first phase:  
 Methods required to produce metaphase spreads. Skin fibroblasts 
are used initially in 1956 for cell culture. After 40 years, 
phytohemagglutinin was identified, which could stimulate lymphocytes 
particularly T cells in blood and was found to stimulate mitosis. Thus this 
analysis made cytogenetic analysis, a diagnostic tool from a research 
method. Finally in 1960, the Philadelphia chromosome was the 
chromosomal abnormality that was associated first with Chronic Myeloid 
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Leukemia. Later, upto 1969, Cytogenetic study was performed with stain 
like giemsa, which stains the chromosomes uniformly throughout the 
length. So, defining became difficult when entire chromosomes were 
stained and were of similar shape and size. So in 1960, a nomenclature 
was framed that groups chromosome depending on size, at the 
Conference  of Denver, which was later modified in 1967 at the Chicago 
Conference.  
 
 (ii) The second phase:  
 In 1969 to 1971 chromosome banding techniques were discovered 
that paved way for second phase of cytogenetics in malignancy. In 1971, 
at Paris Conference, the convention used for numbering of each identified 
chromosome and banding of them was established. In 1972, first 
translocation of chromosomes 8 and 21 [t(8;21)(q22;q22)] was identified 
in AML. It was enumerated that the cytogenetic abnormality Ph 
chromosome was identified to be due to reciprocal translocation 
involving 9 and 22 chromosome [t(9;22)(q34;q11)][1] and not due to 
deletion was found. Proto-oncogenes are associated with breakpoints on 
the chromosomes. So likely, the breakages cause normally functioning 
genes to be disrupted. Thus ACA carry diagnostic and prognostic 
significance.  
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(iii) The third stage:  
 Stage where chromosome regions/genes are identified by the use of 
specific DNA probes. With the introduction of fluorochrome probes that 
paint  specifically different human chromosome and probes that fluoresce 
different genes, many abnormalities are detected. This is called by 
Fluorescence InSitu Hybridization (FISH) technology. Chromosomal 
losses and gains are identified by Comparative genomic hybridization 
(CGH). All chromosome defects are detected by multicolour FISH or 
spectral karyotype methods. With this only the chromosome involved are 
detected but specific region affected in chromosome are not detected. Use 
of Rx-FISH techniques and DNA labelled with flours helps to improve 
the precision of karyotyping.66 Cytogenetic studies is also used to type the 
hematological malignancies and to monitor the disease progression, like 
presence of ACA in CML developed on disease progression in cases who 
had only a Ph chromosome at the time of diagnosis indicates progress to 
acceleration / blast crisis. These studies are also valuable tool to assess 
the success of marrow transplant and impact of chemo on marrow. 
Because in remission after chemotherapy with PTKI a normal karyotype 
is observed. Replacement of abnormal karyotype by donor karyotype 
indicates engraftment after BMT. Prediction of the disease prognosis can 
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also be made based on the cytogenetic abnormality observed as in case of 
AML, M2 t (8, 21) indicates a good prognosis. 
 
CYTOGENETIC PROCEDURES  
 Conventional cytogenetic studies need actively replicating cells 
that are usually obtained in marrow of bones. Highly proliferating cells 
are also seen in lymph nodes, chorionic villi and solid tissues. When 
peripheral blood lymphocytes are cultured, mitotic stimulant like 
phytohemeagglation has to be added to the cells to make them undergo 
mitosis. After capturing the metaphase spread, banding is done with 
giemsa and chromosomes are distinguished individually by observing 
under ordinary light microscope. Usually the specimen choice is based on 
clinical indications of the patient for the chromosome analysis. Presence 
of  hematological malignancies like lymphoma or acute or chronic 
leukemias, the marrow aspirate is the specimen used. 
 
A)  COLLECTION OF SPECIMEN 
 Sodium heparin tubes are used for collection of bone marrow 
specimen which is preservative-free. First few mm of tap from marrow 
have the maximum proportion of cells and they are samples considered 
the best for cytogenetic analysis. Later bone marrow taps are diluted by 
blood and this decreases the number of actively dividing cells. The 
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number of actively dividing cells determines the success of BM. After 
harvesting, transport specimen to lab immediately at room temperature or 
in case of delay that which could not be denied, the specimen should be 
stored at 40 C and must be transported in an ice packed vacuum flask. 
Specimens are processed upon reaching lab at once to avoid death of 
cells.  
 
B) CULTURE MEDIA  
 Samples for cytogenetic studies are cultured in aqueous media like 
RPMI 1640 for good growth. Thus media are solutions of balanced salts 
and are composed of salts, glucose, and buffers to maintain the correct 
pH. These media that are commercially obtained. But still they have to be 
cultured together with antibiotics L-glutamine and fetal bovine serum 
(FBS). As bone marrow contains actively dividing cells, for BM culture, 
phytomeagglution is not added. The amino acid L-Glutamine is  for cell 
growth but it is not stable and it breaks down on storing to form D-
glutamine. Its isomer L-glutamine should be kept frozen to maintain its 
stability. So it should be put into the culture medium just before its use. 
Also required is Serum for better cell growth. Fetal bovine serum of 10-
30% of serum is included into the culture medium. Antibiotics like 
Penicillin/streptomycin, gentamicin, and kanamycin are used commonly 
in culture media to stop the growth of microorganisms. 
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Phytohemeagglutinin, a mitotic stimulant is not applied for bone marrow. 
But, B-cell mitogens like Epstein Barr virus, are used to stimulate 
lymphocytes in case of B-cell lymphoma and many leukemia. Free 
floating cells in blood and bone marrow samples are cultured in tissue 
flasks or sterile tubes. 
 
C)  SPECIMEN PREPARATION FOR CULTURE  
 Either the sample like marrow or blood should be directly added to 
the culture  or WBC separation should be made from whole blood and it 
can be useful to inoculate the culture. White Blood cells are separated by 
keeping it in rest or by doing centrifuge of  the sample. Wait till the blood 
in test tube settles, it will be settled  into 3 unique layers. The heavier 
RBC settles in the lowest layer, plasma tops the most upper layer, and the 
the buffy coat layer i.e the middle layer consists of the WBC. Take away 
the  layer of  buffy coat and resuspend using the culture. Culture the 
marrow cells at 370C  using an incubator. It can be harvested directly 
also, by spending no time in culture, or after giving 24 hours to 48 hours 
culture time for increasing the mitotic index level. Extended duration in 
media are not need, because the cancer cells which are abnornal can be 
lost over the time or normal precursor cells may be diluted which is 
present in.  
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D) HARVESTING CELLS  
 Once the cultures are grown for prescribed duration of time and 
sufficient counts of dividing cells are there, the harvesting of cells can be 
done. While harvesting the first step  include the collecting of dividing 
cells that are in metaphase, followed by treatment using hypotonic media, 
fixation and the placing the chromosomes on the glass slides, to stain and 
examine microscopically. A inhibitor i.e mitotic, colcemid is analogue of 
the drug colchicine which is normally  suggested and used in order to 
attract enough count of cells at the metaphase. The tubulin is binded by 
the Colcemid, which is a protein, obstructing the formulation of the 
spindle fibers or removing the spindle fibres already there. Thus avoids 
the separation i.e the sister chromatids’ separation in anaphase, favours 
grouping of cells at metaphase. The essential step is the exposure time to 
colcemid. The longer the duration higher the metaphases  is collected. 
Actually they are shorter, because of the condensation of the 
chromosomes on progression through the metaphase. Longer 
chromosomes should be taken for studies. After exposing cells to 
colcemid, the hypotonic solution is added. Water enters the cells by 
osmosis, results in cell swelling. This step is very important for  enough 
chromosomes spreading on the glass slide. Timing is the very crucial 
factor. Cells bursting may be caused by the longer duration of exposure 
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and similarly chromosomes clumping may be caused by shorter duration 
of exposure. Some hypotonic solutions can be useful, namely: 0.075M 
potassium chloride (KCl), 0.8% sodium citrate, dilute serum,  diluted 
balanced salt solutions, and mixtures of KCl and sodium citrate. The type 
of hypotonic solutions we use affects the chromosomes morphology. 
Fixative containing or consists of 3 parts of absolute methanol and one 
part of glacial acetic acid stops the hypotonic solution action and also 
fixing the cells at the swollen stage. The modified carnoy’s lyses the rbc 
in the sample. Every time fresh fixative must be prepared before it can be 
used because it can get diluted by absorbing water in the atmosphere. The 
fixed cell suspensions are dropped on the glass slides. And the 
concentration of suspension is adjusted to get most favourable results.  
 
A high-quality slide grounding must have: 
• adequate quantity of metaphases. Cells should not be packed out on 
the slide,  
• Metaphases that are spread well with minimal chromosomes 
overlap, 
• No observable cytoplasm.  
 
 Elevation of high temperature and moisture enhances the 
chromosomes distribution, whereas cooler, reduced temperature and 
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lesser humidity decreases the chromosomes spreading. Higher duration 
exposure to treatment of hypotonic media makes the cell more easily 
broken and also increases the spreading. But an insufficient exposure to 
hypotonic solution makes the cells difficult to burst.    
 
Variables during the slide preparation include:-  
• height from where the cells are dropped;  
• use of wet slides or dry slides;  
• use of cold slides, room temperature slides, or warm slides;  
• use of air or flame or steam drying of the slides;   and  
• the angles at which the slide is spread and/or pipette is held.   
 
 The slides should ‘aged’ overnight at 600C or at 900C for 1 hour to 
enhance chromosome banding. It can also done by brief exposure of the 
slides to UV light67. 
 
E) BANDING AND STAINING OF CHROMOSOME  
 Techniques of Chromosome staining and colour banding are of 2 
broad categories:  
 
i) First technique produces specific bands that alternate 
throughout the length of the chromosome, and  
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ii) Second technique, stains only a particular region of some 
chromosomes or all of the chromosomes.                                                         
 
Techniques that produce banding along the length of each chromosomes 
include:  
• Giemsa banding, 
• Quinacrine banding and  
• Reverse banding. 
 
 This technique helps in positively identify each of the  
chromosome pairs and it also permits the categorization of the structural 
abnormalities. Resolution  of banding is an account of the consecutive 
light /dark bands number in a haploid set. The minimum band resolution 
is  400 bands. Good banded, moderately increased resolution metaphase 
have 500-550 band range, and prometaphase  have a resolution of  
exactly 850 or more bands range.  
 
GIEMSA BANDING: 
 G-banding is the most commonly used routine banding system. G 
bands formed with trypsin and stain like Giemsa or GTG banding is a 
banded techniques among many. The slides that are aged are treated with 
enzyme trypsin and stained with Giemsa. Other than Giemsa stain, others 
like Wright or Leishman stain are also involved.  A light/ dark band series 
  
25 
 
are also produced which helps in the notification of each chromosome. 
The dark band that are A-T rich, with heterochromatic introns in the 
chromatid, whereas the bands that are light have G-C rich areas, with 
euchromatic regions. The most active regions are G-light bands compared 
to the dark bands which have comparatively minimal number of active 
genes.  
 
Q-BANDING: 
 This fluorescent technique is like G-banding  pattern but with very 
few exceptions. The large pericentromeric and polymorphic regions of 
chromosomes 1 and chromosome 16, and the end of long arm (q) of the 
chromosome Y which brightly fluoresce. The end of long arm of 
chromosome Y is the site with most fluorescent activity in the genome of 
human. In the advantage of Q-banding is that, it confirms the presence of 
Y , but the negative advantage is that this is not permanent, as it is a 
fluorescent stain and require the use of fluorescence microscopes which 
are most expensive and a dark room.  
 
R-BANDING: 
 The technique of R-banding creates a banding pattern which is 
reverse or opposite pattern of G-banding. Available are fluorescent and 
methods that are nonfluorescent. Human chromosomes inherit 
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euchromatic terminal ends or telomeres that are difficult to vizualise with 
standard Giemsa band techniques as the telomeres which are pale regions 
on chromosome ends may hide into the background. R-banding helps in 
identification of these telomere.  
Methods that stain selective regions in chromosome include: 
 
• Constitutive heterochromatin staining  
• Telomere banding or T-banding 
• Cd staining 
• Giemsa at pH 11 or G-11 banding,  
• Silver staining for nucleolar organizer regions or NOR staining and  
• 4,6Diamino-Phenole-Indole/Distamycin A or DAPI/DA staining.  
 
C-BANDING: 
 It is a technique that particularly stain the constitutive 
heterochromatin located among the centromeres, the regions of inherited 
variations located on chromosomes 1, chromosome 9, chromosome 16, 
and the end of long arm (q) of the chromosome Y. This banding is helpful 
for studying marker chromosomes and determining the presence of 
pseudocentric and dicentric chromosomes.  
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TELOMERE BANDING: 
 Telomere banding helps in locating only the terminal ends or 
telomeres of the chromosome stained.  
 
CD STAINING: 
 CD staining procedure produces a dot pair one for each chromatid 
at each centromere. Only the functionally active centromeres will be 
stained. This staining is used to classify functional from not functioning 
centromeres and to study the presence of translocations, to locate ring 
chromosomes and to study marker chromosomes.   
 
G11-BANDING: 
 This banding technique particularly stains the heterochromatin 
areas of chromosomes  1, chromosome 9, , chromosome 16, the end of 
long arm of chromosome Y, and the satellites regions of the involving 
acrocentric chromosomes. G -11 banding is also used to classify between  
human and other chromosomes in hybrid cells.   
 
NOR STAINING or AgNOR: 
 AgNOR staining particularly stains the nucleolar organising 
regions located on the stalks of the every acrocentric  chromosomes. 
Silver staining of nucleolar organising regions stains particularly the 
active  ribosomal  genes. This silver staining of nucleolar organising 
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regions helps  to identify the marker chromosomes and to study the 
rearrangements or variations involving every acrocentric chromosomes.  
 
DAPI/DA STAINING: 
 This  staining combines, a fluorescent dye, along with distamycin 
A, which is not a fluorescent antibiotic. These DAPI/DA create stable 
bonds like A-T rich areas and double stranded regions of DNA. 
DAPI/DA fluoresce few A-T rich regions of constitutive heterochromatin 
in the band region c of every chromosomes 1, chromosome 9 , 
chromosome 16, and end of long arm of Y chromosome, and the short 
arm (p) of chromosome 15. This method is used to find rearrangements of 
chromosomes 15 and to confirm variations over  polymorphic areas of 
chromosomes 1, chromosome 9, chromosome 16, and end of long arm of 
chromosome Y and to find marker chromosomes. 
 
CYTOGENETICS – AUTOMATION: 
 Cytogenetic methods are quite difficult and depend on man power. 
Instruments such as robots that harvest, controlled drying units, and 
imaging systems which are computerized have been designed to assist the 
lab in sample preparation and identification of chromosomes. Some 
laboratories doing cytogenetic studies use all the above said automations, 
some use few, and some never use any methods.    
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A) ROBOTIC HARVESTERS  
 These harvesters do harvesting of actively dividing mitotic cells  
for cytogenetics  after the addition of mitotic inhibitor colcemid which 
produce metaphase arrest. The robotic machine can perform aspiration, 
removal and taking in of hypotonic  solution, and as well as fixing of 
cells. The incubation  times should be programmed within computer for 
each step that runs the robot. 
 
B) DRYING CHAMBERS  
 Helps in spreading chromosomes by keeping one or more drops of 
above said suspension of cells on slides. Metaphase spread is controlled  
by height of fall of the suspension, procedure temperature and the 
conditioning of the spread, air flow and humidity of the surrounding 
room.  cell suspension dropped over the slides dries and the fixative has 
pulling action on the cell membrane over the slide, making the metaphase 
cells to spread across. There are commercialy available Conditioned 
controlled units where air flow, humidity and temperature is maintained 
and can be maintained for slide preparation.   
 
C) COMPUTERIZED IMAGING  
 The traditional method of cytogenetics  involve the principle of   
photo capturing from microscope after the location of appropriate 
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metaphases by use of an England finder. Camera is attached over the 
microscope to take pictures of spread of chromosomes. The film is 
processed in room that is dark. The cell spreads with metaphase are 
paired after cutting, but this procedure consumes lot of time. This process 
can now be done using a computerized imaging method. The metaphase 
spreads can be captured by image acquisition subsystem.  The subsystem 
consists of a camera over microscope with an adapter, CCD, a grabber for 
frame and an expensive image capture software. Dedicated imaging 
software can do either automatical or semi-automatical karyotyping, 
banding analysis and ideogram display which are all now available 
commercially. Components like  metaphase finding, multicolour FISH 
analysis, Comparitive Genomic Hybridization analysis can be included. 
Captured metaphase spreads in the digital form are analysed by the 
Cytovision satellite capture station. This image is made to transfer into 
the Cytovision workstation where karyotyping method is performed. 
Karyotyping in this method is done semi-automatically. The manual 
checking by geneticists should be done to assure that the chromosomes 
are correctly arranged and paired. A hardcopy is produced by laser printer 
consisting of the metaphase spread and karyotype. The metaphase spreads 
and karyotypic patterns are stored in the form of  files on the optical 
disks.68 
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A) CYTOGENETIC ANALYSIS REQUIREMENTS FOR 
NEOPLASTIC STUDIES   
 Cytogenetic analysis can be done from marrow aspirate of long 
bones or ileum, peripheral blood that is not stimulated or from biopsy of 
tumor or aspirate.  Cells are karyotyped according to the ISCN, 2013.  
Complete karyotyping of 25 cells are done and all 25 metaphase spreads  
are analysed. At least  two karyotypes should be prepared from each cell 
line if >one cell line is present with a resolution of at least 400 bands. If 
there is <20 analysable cell plates with an abnormality detected, the 
number of normal and abnormal cells (if any) is detected. If there is less 
than 20 examined cells and if  abnormality is not been detected, the 
number of cells studied is reported and many additional procedures like 
FISH and molecular studies could be done if clinical condition warrrants. 
Additional metaphases may be examined for studies of minimal residual 
disease or marrow transplant. 
 
B) FAILURE OF CULTURE 
Failure of Bone marrow culture may be due to:                                                         
i) the specimen  submitted to the laboratory is inppropriate, which 
include blood drawn from periphery with no blasts collected 
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instead of marrow. This may be the result of the wrong 
specimen tube being collected.  
ii) specimen submitted to the Laboratory is insufficient 
iii) no living cells in the sample due to delay in sample 
transportation or improper storage of sample, that is sample not 
kept at 40C and not transferred in ice if delay is not avoidable. 
iv) catastrophic equipment failure in laboratory. 
v) Reagent worn out. 
vi) interpretation error (most unlikely).  
 
CYTOGENETIC ABNORMALITIES  IN CML:                                                                                             
 In patients with chronic myelogenous leukaemia (CML),  the break 
points are heteromorphic or polymorphic on the long arm of chromosome 
22 (22q) producing the Philadelphia (Ph1) chromosome which is 
heteromorphic in size for the long arm of chromosome 22. Four types of 
Philadelphia  chromosomes are proposed based upon the break points and 
with the relative size of chromosome. They are: Types I (very large), type 
II (large), type III (average) and type IV (small) with respective break 
points at bands 22q13.3, 22q13.1, 22q12 and 22q11.3, respectively. Since 
the break points are considered arbitrary and hence these types are not 
considered absolute as they are based on length differences. Since types I 
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and II are difficult to recognize by conventional techniques, the RFA 
technique that is Reverse band by fluorescence with acridine orange 
should be performed on all cases.69 Addition to the most common and 
characteristic Philadelphia (Ph) chromosome t(9;22)(q34;q11), the 
frequency of ACA, additional chromosomal abnormalities has an 
incidence of 7% in chronic phase and increases to 40–70% in advanced 
disease/blast crisis.[70][71] Progression from chronic phase to accelerated 
phase or blast crisis is often associated with additional chromosomal 
aberrations like  trisomy 8, trisomy 19, duplication of the Ph 
chromosome, monosomy 7,  acquisition of t(1;21), isochromosome 17q 
(leading to the loss of p53 gene on 17p), or inversions and translocations  
associated with AML/myelodysplasia72, which translates a genomic 
instability of  cells and the appearance of BCR-ABL1 kinase mutations, 
both of which can confer resistance to tyrosine kinase inhibitors.[73][74]  
Very few cases of lineage switch in CML have been reported in the 
literature before75 and during the imatinib era76. The karyotype analysis 
showed that the chromosomal aberrations occurring in addition to the 
Philadelphia chromosome (Ph1) were  non-random strictly. In a study, 
88% of the total cases with further changes, at least any one of the three 
main chromosomal aberrations wasdetected. An extra Philadelphia, 
trisomy 8 and/or trisomy for the long arm of chromosome 17 were 
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observed in all cases studied.77 Variant translocations occur in 5%-10% of 
patients, and  [t(v;22)] are characterized by the involvement of one or 
more chromosomes in addition to chromosomes 9 and 22.78  On treatment 
with imatinib, patients with variant translocations and standard 
translocations standard translocations  had a similar prognosis.79 Patients 
with variant translocations have deletions in derivative chromosome 9 
[der(9)], that were a key prognostic factor in the pre-imatinib era, 
occurring mostly in t(v;22) patients.80 The loss of the negative prognostic 
impact of der(9) deletions with imatinib contributes to the fact that 
variant translocations does not have negative prognosis.81 Near haploid 
leukemia stemlines were also reported82. Other than the additional 
chromosomal abnormality, disease progression is found to associate with 
marker chromosomes. Multicolour FISH  studies has enabled the 
detection of the marker chromosomes83. Correlation among the type of 
additional chromosomal  aberration along with the phenotype of  blast 
crisis has been established. Hyperdiploidy, trisomy 8,  trisomy 19, 
,trisomy 21 and  isochromosome(17q) are linked with myeloid blast 
crisis. An extra Philadelphia is seen both in both myeloid and lymphoid 
crisis. Chromosome loss is rarely seen compared to chromosome gain in 
blast crisis. If loss is seen, monosomy 7 is the most common. They 
precede the blast crisis by 2-4 months. Especially in an upcoming blast 
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crisis, following up with cytogenetics would be a valuable measure for 
monitoring of  the progression of  course of disease[1]. 
 
VARIANT PHILADELPHIA TRANSLOCATIONS: 
 Variant translocations occur in 5%-10% of patients, i.e,  [t(v;22)], 
are considered by the involvement of one or more chromosomes along 
with chromosomes 9 and 22.84    The mechanisms of the creation of the 
variant translocations are not  clear; some have optioned two different 
mechanisms of origin:  one step mechanism in which chromosome break 
is occuring instantaneously on 3 or 4 different chromosomes in a 3 or 4-
way changes, respectively, and a two step mechanism involving 
subsequential translocations in which a standard Philadelphia t(9;22) 
translocation is followed by another translocation involving additional 
chromosomes.85  The 2-step mechanism suggests that the  variant 
translocation is like clonal evolution, and thus this mechanism could be  
an association with a poorer prognosis.86 The mechanism of variant 
translocations can be detected by FISH technique used at present. In the 
era prior to imatinib, some studies reported a strong association of variant 
translocations with the presence of der(9) deletions,but this is 
disproved[87][88][89] suggesting a poor prognosis which may be due to the 
increased frequency of the der(9) deletion changes. 
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PHILADELPHIA NEGATIVE CML: 
 More than 90% of patients diagnosed with a morphologic picture 
of chronic myeloid leukemia (CML) demonstrate the characteristic 
reciprocal Philadelphia chromosome (Ph) karyotypic abnormality, 
t(9;22), by conventional cytogenetic analysis.90 The remaining 10% of 
patients are classified into Ph negative CML or ph with additional 
chromosomal abnormality by conventional cytogenetic method of 
karyotyping. In these cases, the bcr/abl gene rearrangement is found out  
by molecular studies in 25–50%. Patients in this group are classified with 
Ph negative bcr/abl positive CML.  
 
 Studies identified a well characterized group of patients with 
Philadelphia negative, bcr/abl negative CML. This group represents 2.9% 
of all patients with CML who were seen at The University of Texas M. D. 
Anderson Cancer Centre between 1967 and 1999.91 A median survival of 
25 months is seen in Patients with bcr/abl negative CML from the time of 
diagnosis.92 in another study the median survival of 50 months is seen in 
patients with Ph negative, bcr/abl positive CML, with a survival similar 
to that has been  reported for patients with Ph positive CML.93 These 
finding provide further support, that Ph negative, bcr/abl positive CML is 
indistinguishable clinically and  biologically from Ph positive CML.94 
adverse features assoiated with survival are Older age, low platelet count, 
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low haemoglobin(anemia), and increased percentages of blasts in 
eripheral blood. By multivariate analysis, older age, anemia, and severe 
leukocytosis as variables that were associated independently with poorer 
prognosis. Diploid karyotype is seen in two thirds of patients. Trisomy 8 
was the most common abnormal karyotype observed in cases with 
additional abnormality. Frequency of additional chromosomal 
abnormalities was about 30% in both the bcr/abl negative group and the 
bcr/abl unknown group. Similar reports are obtained from the previous 
studies.95   
 
FISH ANALYSIS (FLUORESCENCE INSITU HYBRIDIZATION): 
 This procedure is done on bone marrow cells using DNA probes 
that hybridize at the BCR and ABL regions prepared by the standard 
cytogenetic techniques . The most frequently used probes were: Dual-
Fusion Translocation Probe (Abbott Molecular-Vysis), the Locus Specific 
Identifier BCR/ABL Dual-Color, or the Double-Fusion Signal D-FISH 
BCR/ABL Probe. Probes for ABL and BCR gene regions uses fusion 
strategy in dual fusion technique. A normal nucleus will exhibit 2 orange 
and 2 green signal patterns; one orange (normal 9 chromosome), one 
green (normal 22 chromosome) in the nucleus is seen with a classic 
t(9;22) translocation, and derivative chromosomes der(9) and der(22) 
show 2 yellow fusion signals in the nucleus.96 The Locus Specific 
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Identifier BCR/ABL Extra-Signal Dual-Color Translocation Probe uses 
an extra signal. The nucleus with a classic Philadelphia t(9;22) 
translocation will display 2 orange signals on normal chromosome 9 and 
der(9), and one  fusion signal yellow on der(22). 
 
 Hybridization pattern varies in cases with structural changes 
involving chromosomes 9 and 22 or with a variant Philadelphia  
translocation. Slight modifications were done for Hybridization 
procedures according to the manufacturer's recommendation. A pool of 
PAC, RP5-1132H12, and RP5-835J22 known as PAC/BAC system is 
used in only one laboratory for the ABL gene and for the BCR gene, 
BAC and RP11-164n13 is used.97 200-300 nuclei on metaphases are 
analysed in FISH analysis to localize the rearrangements. 
 
MOLECULAR GENETICS OF CHRONIC MYELOID 
LEUKEMIA: 
INTRODUCTION TO MOLECULAR STUDIES 
 In B-cell or T-cell lymphoproliferative  disease, evidence of 
clonality for gene rearrangement can be studied by Molecular studies. 
This also helps to identify certain chromosomal translocations associated 
with the leukemias. Other techniques for gene rearrangement are 
Southern blot hybridization, pulse gel electrophoresis and polymerase 
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chain reaction (PCR). For detecting the  bcr-abl gene rearrangement in 
CML, polymerase chain reaction is used for the detection of nature of 
transcripts, for the presence of the b2a2 and b3a2 transcripts. The 
presence of one of the b2a2 or b3a2  transcripts indicate that the patient 
has CML.  
 
POLYMERASE CHAIN REACTION (PCR): 
A) INTRODUCTION TO THE PCR  
 Kary Mullis is the person who invented polymerase chain reaction 
(PCR) in 1985.98 principle pf PCR is to amplify a small segment of DNA 
over a billionfold. The substrate used in PCR are a pair of 15 to 50  
oligonucleotide primers, DNA  polymerase, deoxyribonucleotide 
triphosphates (dNTPs) , and buffer. oligonucleotide primers are 
sequences with a length of 15 to 50 oligonucleotides, which are 
synthesized against opposite strands of DNA that has to be hybridized 
several kb apart. The oligonucleotides prime the synthesis of DNA on the 
DNA template. Each cycle in PCR consists of a set of 3 steps which are 
repeated under different temperature controlled conditions in succession.  
 
I) HEAT DENATURATION 
 The first step is to dissociate (double stranded) ds DNA which is a 
template into two strands by means of heating at high temperature. 
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II) ANNEALING OF PRIMERS  
 On lowering the temperature, two DNA strands reassociate 
forming primer-template complex as excess of oligonucleotide primers 
are present when compared to DNA templates.  
 
III) PRIMER EXTENSION (AMPLIFICATION STEP)  
 The third step is the formation of complementary DNA  where the 
oligonucleotides attach to the extending end of the primer DNA by use of 
DNA polymerase. The extension occurs from 5’to 3’ direction of each 
annealed primer on the complementary DNA (c-DNA) strand.  
 
 These 3 steps completes one entire cycle. Generally in PCR,  25 to 
30 or more cycles are performed using the newly synthesized DNA 
fragments acting as template for the synthesis of new DNA strand in next 
cycle. Thus for the new  DNA synthesis the fragments of DNA 
synthesized in the previous cycles becomes templates. These 3 steps can 
be automatically done using a thermal cycler. The amount of  DNA 
fragments formed in each cycle increase exponentially  at a rate of 2n,  
where n equals the number of cycles performed. Products formed in the 
PCR consists of DNA fragments with lengths that are uniform in all 
fragments. These DNA fragments are the products of oligonucleotide 
priming. Amplicon  or target sequence are products with nucleotide 
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sequences that are complementary to oligonucleotide primers.  However, 
the exponential amplification is not limited process but continues 
uninterrupted. Efficiency of each cycle in PCR is governed by number of 
factors.  
 
Factors are : 
• The amount of enzymes 
• The amount of substrates added 
• Temperature conditions. 
 
 Effect of these factors is more pronounced in later cyles of PCR. 
The enzymes are exhausted  after 2530 cycles of PCR due to production 
of excess amounts of target. The activity of the enzymes are reduced due 
to thermal denaturation. Reannealing of target strands occurs when target 
strands concentration increases. This competent increase of target strands  
competes  with primer annealing99. The effectivenss of PCR is such that it 
can amplify the DNA fragments that are very small as much as 5 kb.  
But the disadvantage is that PCR is not too good for amplifying larger 
fragments of DNA. In case of large DNA fragments, there is difficulty of 
synthesizing DNA of sufficient length  from one primer and to make that 
primer strand  to serve as a template strand  for the other primer in the 
next amplification cycle.  
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Uses of PCR include: 
• Disease diagnosis 
• identification  of species 
• detection of viral or bacterial infection  
• prenatal diagnosis  
• forensic sciences  
 
B) COMPONENTS OF THE PCR  
The basic components used in PCR  include the following: 
• DNA polymerase 
• DNA template 
• dNTPs   
• primers,  
• magnesium chloride (MgCl ),  and  
• buffer.  
 Some come in kit form.  
 
(I) DNA TEMPLATE  
 Two DNA template are usually provided by the researcher or 
clinician. In general, lengthy DNA template sample preparations are not 
required for the PCR to work efficiently. Even crude DNA samples can 
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be used as templates as the technique of PCR is highly sensitive. simple 
boiling itself will help in extracting DNA from samples like paraffin 
embedded tissue block sections or ancient samples are also used in PCR. 
As only short intact nucleotide sequences are required for PCR, however 
crude the DNA samples may be, they can be analysed in PCR.  
 
(II) PRIMERS  
 Required Primers for each case can be prepared from preformed 
genetic sequences which are available from sources such as EMBL OR  
GENEBANK.  These genetic sources have nucleotide sequences which 
are evolutionary conserved sequences or they contain sequences based on 
existing sequences of close similarities. Primers can also be designed 
from already known information of sequences of amino acid. Features of 
primer that affect the PCR are the composition of primer, which must 
contain sequences that atleast match 50% of template sequence and the 
ability of the primer to form primer-dimer structures or that it should be 
complementary to itself. Both of these factors affect the PCR.100 Many 
computer programmes are available currently to aid in the process of 
designing primer and optimization of annealing temperatures. 
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(III) THERMOSTABLE DNA POLYMERASE  
 DNA polymerase 1 with its Klenow fragment is used in the initial 
development of the PCR. DNA polymerase 1 is the enzyme used to carry 
out the extension step of the PCR. It is a heat labile enzyme. Because of 
its lability to heat, during every step of PCR, enzyme should be added 
freshly as the enzyme is denatured by the high denaturation temperature. 
This step of addition of enzyme in each step incurred more cost and made 
the technique labour intensive. But this difficulty is overcome by the 
thermostable DNA polymerases. These DNA polymerases which are 
thermostable made PCR a fully automated technique as the enzyme 
needed to be added only once. The Taq DNA polymerase is the most 
commonly used first thermostable DNA polymerase. It is produced from 
bacterium Thermus aquaticus (Taq) which is found in the hot springs of 
Yellowstone National Park. Taq and recombinant form of taq which is 
Amplitaq have 5’-3’ exonuclease activity. It is stable at an optimum 
temperature at 720 C. These two complementary DNA polymerase lacks 
3’–5’ proofreading exonuclease activity. This property made it as the 
cause for wrong  incorporation of nucleotides.   
 
 The Stoffel fragment DNA polymerase, derivative of taq DNA 
polymerase enzyme, is  highly thermostable and is less sensitive to 
changes in Magnesium concentration. The Stoffel fragment DNA 
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polymerase, has no 5’ – 3’ exonuclease activity. Stoffel fragment 
polymerase is aids in amplifying G-C rich  regions. Since G – C rich 
regions require high or prolonged temperatures, thermostable Stoffel 
fragment DNA polymerase are required.  There are numerous DNA 
polymerases available and marketed commercially. highly thermostable 
DNA   polymerases known as  VentTM DNA   polymerases is isolated 
from the bacterium Thermococcus litoralis. These bacteria are found in 
the floors of  deep oceans and have capacity to extend templates in excess 
of 12 kb pairs. These DNA polymerases have higher fidelity and 3’ – 5’ 
proof reading ability when compared to Taq DNA polymerases. A 
derivative  of the bacterium Thermococcus litoralis lacking the activity of 
exonuclease enzyme which is 3’ – 5’ proof reading activity is also 
available known as   Vent (exo -)TM. Also a form of DNA polymerases 
with very high thermostability known as (Deep VentTM) are also 
commercially available.  
 
 Hyperthermophilic variant which is a marine derivative 
synthesized from the hyperthermophilic archaebacterium  Pyrococcus 
furiosus  (pfu).this   Pfu DNA polymerase also contain 3’-5’ proof 
reading activity  and incorporates radiolabeled analogues and nucleotides  
efficiently. Pfu DNA polymerase is very useful  for producing 
radiolabeled gene probes. Pfu DNA polymerase also helps in cycle 
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sequencing techniques. However, degradation and modification of  
primers  and template can be caused by the 3’ – 5’ exonuclease activity of  
Pfu DNA polymerase. Hence, this enzyme must be added last when 
preparing the reaction. A mutant clone of Pfu DNA Polymerase called 
Pfu DNA Polymerase (exo-) which is a genetically engineered product 
has no 3’ – 5’ exonuclease  proof reading ability is also commercially 
available. A recombinant form of DNA polymerase and its modified form 
obtained from Thermotoga maritima (Tma) from the DNA polymerase 
gene of Thermotoga maritima called as UITmaTM DNA polymerase is 
available. Tma is a hyperthermophilic, Gramnegative true bacterium. 
Thermotoga maritime was isolated  by heating the marine sediments 
geothermally in Italy.  
 
 A DNA polymerase with reverse transcription activity known as 
Tth DNA polymerase is available. It is formed from Thermus 
thermophilus (Tth), which could perform reverse transcription reactions 
in the presence of Mn2+ at 70 0C. After chelation of Mn2+ and DNA 
synthesis, the polymerase can carry out polymerization of the template. 
This dual activity of reverse transcription reactions and DNA synthesis 
has made the Tth DNA polymerase as a best choice for RT-PCR to be 
carried out in a single tube.101  
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IV) OTHER COMPONENTS OF THE PCR: 
 The DNA polymerase requires MgCl2 for efficient activity and in 
the extension step of the PCR for incorporation of dNucleotide 
Triphosphates. MgCl2 concentration also affects the specificity of  the 
DNA template and primer interaction. MgCl2 concentration increasing the 
melting temperature thereby affecting the denaturation of the double-
stranded  DNA template. Concentration of MgCl2 is important in such a 
way that  low yields are due to Insufficient Mg2+ Concentration whereas 
non specific products are formed when concentration of MgCl2 is in 
excess. pH has to be maintained at 8.3 at room temperature. This is 
achieved by the buffer/salt composition. 50mM KCl and 10mM Tris-HCl 
are the usual components of the buffer/salt composition. changes in  
temperature cause  significant changes in pH when tris-HCl is used as 
buffer. This Ph change may especially affect the amplification of long 
fragments102.  
 
 However MgCl2 and PCR buffers such as 50mM KCl and 10mM 
Tris-HCl can also be prepared manually depending on the requirements 
of the sample load in each laboratory. Commercially available kits 
contain DNA polymerase, buffers and Mgcl2 together. 
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C) HOT START  
 When primers that are degenerating are used mispriming of  
oligomerization of DNA occurs. ‘Hot start’ technique been used to 
increase specificity  of the polymerase chain reaction. By this technique 
the separation of one or more of the important reagents of the PCR 
occurs. nonspecific annealing of primers are prevented by using hot start 
technique. Hot start technique helps in mixing of all reaction components 
after the DNA template are denaturation. PCR using the hot start 
technique minimizes to nontarget DNA sequences and decreases primer 
oligomerization.  
 
D) CONFIRMATION OF PCR PRODUCTS  
 Agarose gel electrophoresis  helps in confirmation of the amplified 
PCR products. Restriction endonucleases can also be used for 
confirmation of PCR products. These restriction endonucleases works 
based on the presence of a appropriate restriction site within the amplified 
sequence. A DNA binding  fluorescent dye is used to stain the gel. The 
fluorescent dye used is ethidium bromide which stains the dye and results 
are viewed under ultraviolet light103. Southern Blot analysis also helps to 
confirm the amplified PCR products. Following this technique 
hybridization  with  appropriate DNA probes are done.   
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 Second round of PCR can be done on products that are produced 
by amplification of DNA fragments in first round of PCR. This second 
round can be done by nested PCR technique whereby nested 
oligonucleotide primers  that corresponds to the sequences that are 
present within the amplified DNA sequence is used. 
 
False-positive reactions  in PCR may be due to: 
• False priming either on the genomic DNA or on the primers 
themselves can occur. Hence irrelevant DNA fragments are formed 
on amplified fragments.   
 
E) CONTAMINATION PROBLEMS OF PCR  
 As the technique of PCR is highly sensitive technique, even minute 
contamination may cause amplification of wrong DNA fragments. care 
taken should be utmost to avoid contamination. Potential sources that 
cause gross contamination are DNA from previously amplified products 
or DNA included during sample preparation. Contaminating DNA 
fragments from previously amplified products are found on pipettes, 
laboratory surfaces   and even aerosols. Inorder to avoid such gross 
contaminations, units where reactions of PCR are done should be set up 
in a separate sterile locations within a laboratory.  
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 DNA extraction regions should be kept separate from PCR 
reactions processing locations. Microcentrifuges and pipettes should be 
sterile which are used in the PCR   laboratory. Suitable positive and 
negative controls has to be run every time while a sample is run.104.    
 
F) INHIBITORS AND ENHANCERS OF PCR  
Inhibitors of PCR are: 
• Heparin. Hence heparinized tubes should never be used for sample 
collection and only EDTA sample should be used. Blood collection 
in EDTA prevents coagulation.  
• Porphyrin compounds found in blood, are also strong inhibitors of 
PCR. lysis of red blood cells and problems with white cell pellet 
formation occurs with Porphyrin.  . 
 
Other inhibitors include  
• SDS,  
• Proteinase K and  
• Phenol, the commonly used reagents in nucleic acid extraction. 
 
Enhancers of PCR include : 
• Formamide,  
• Dimethylsulfoxide,  
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• Polyethylene glycol,  
• Glycerol, and  
• DNA-binding proteins.   
 
REVERSE TRANSCRIPTASE-POLYMERASE CHAIN 
REACTION (RT-PCR): 
 Single stranded RNA cannot be amplified by using PCR as it 
requires DNA template. However RNA can be amplified by producing 
cDNA from ssRNA with the help of enzyme reverse transcriptase. For 
this, dNTPs and an oligonucleotide primer which is complementary to 3’ 
end of RNA to be amplified should be added. In presence of reverse 
transcriptase enzyme which act as a catalyzer in this reaction produces 
cDNA from  the RNA template. This cDNA template which is produced 
in the above reaction act as template for first round of PCR. Though it has 
many applications it is mainly used for assessing the transcriptional 
activity of genes and gene isoforms.  
 
Uses: 
• mRNA expression can be quantified 
• Differential gene expression can be analysed 
• cDNAs can be cloned without producing cDNA library. 
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 Though entire sequence are amplified in the standard PCR 
technique it is efficient in amplifying DNA fragment of < 5kb. DNA 
fragment which is more than 5kb containing both introns and exons are 
not suitable for PCR. Whereas in RT-PCR the resulting product is shorter 
as a result of splicing of  the introns in the RNA and hence the end 
product cDNA. So instead of original DNA. 
 
 So PCR can be performed on the cDNA instead of the  original 
DNA.  
 
DETECTION OF FUSION GENES BY RT-PCR:   
 RT-PCR can be used to detect fusion genes as a result of 
chromosome translocation. Here  both gene 1 and gene 2 are located on 
the same chromosome  but at a distance greater than 20 kb which makes 
it impossible for PCR or southern blot hybridization  to detect the 
translocation. To make detection possible the length of fragment has to be 
shortened by first transcribing it into RNA. Then the nuclear RNA is 
converted into mRNA by splicing and processing thereby removing the 
nucleotide bases present in between the  gene 1 and gene 2. This mRNA 
forms the RNA template for RT PCR.  
 
 With the help of enzyme reverse transcriptase cDNA template is 
produced from mRNA. PCR is then performed on cDNA as template and 
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gene rearrangement produced as a result of chromosomal translocation is 
identified.[99] 
 
 RT-PCR of total RNA or mRNA can be performed by either one 
step or two step RT-PCR method. 
 
 One-step RT PCR  - whole reaction from  the production of cDNA 
to PCR amplification take place  within a single tube. 
 
The advantage of one step RT-PCR: 
• Chances of contamination is less  
• The procedure is simple as there is no need to transfer the cDNA 
synthesized  into another tube for PCR 
• Quick, sensitive and  
• Results are  reproducible. 
 
Disadvantage : 
 Starting RNA template produced here prone to degrade, hence it is 
not used when repeated assays from the same sample is required. 
 
 Two-step RT PCR - Here the reverse transcriptase reaction and 
PCR amplification take place in two separate tubes. 
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Advantage: 
• More accurate then one step RT PCR 
 
Disadvantage: 
• Contamination is more due to more frequent handling of sample105 
• Promega is the Access RT-PCR system supplied by the 
manufacturer. Here the enzyme, reverse transcriptase and DNA 
polymerase used by the manufacturer are produced from Avian 
Myeloblastosis virus  and thermos flavus.104 
  
MOLECULAR MAKE-UP OF THE FUSION GENE:       
 The chromosomal breakpoint 9q34.1 corresponds to proto-
oncogene c-abl which is the region corresponding to breakage in the 
t(9;22) translocation. C-abl  gene represents the normal homologue of the 
transforming gene of Abelson murine leukemia virus, which causes  B 
cell leukemia. The length of this gene is found to be 230kb, encoding at 
least 11 exons and its  5’end is oriented  towards the centromere. Exons 
a1 and b1 are the two alternative first exons that are discovered.  
 
 Distance from Exon a1 to exon 2 is 19kb upstream, while distance 
from exon b1 to exon 2 is > 200kb upstream. Because of this genomic 
variation two types of mRNA transcripts are produced: one with 6-kb 
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mRNA coding from exons a1 to exon 2 with all its 11 exons, and 7-kb 
mRNA which codes from exon b1 to exon 2, skipping the 200-kb 
distance106. The protein product identified previously was p145 KD 
molecular weight. This protein corresponds to p145abl. This protein has 
weak tyrosine kinase activity. The protein is found to be associated with 
tyrosine phosphokinase enzymes thus indicating their involvement in 
normal cell growth control.  
 
 The breakpoint on chromosome 22q11.2 corresponds to breakpoint  
cluster region (bcr) gene on chromosome 22. The length of bcr gene is 
130kb and trancribs into a 4.5 and 6.7-kb mRNA. The translation of this  
bcr gene with 4.5 and 6.7-kb mRNA produces 160-kD protein, p160bcr.  
This oligomerizes, autophosphorylates and transphosphorylates many 
other protein substrates. The increased tyrosine kinase activity of the bcr 
abl gene is due to the potentiating activity of the first exon sequences of 
the bcr gene which potentiates the tyrosine kinase of the abl gene when 
fusion of the gene occurs due to translocation. 89% of CML patients 
develop breakpoint within the first 175-kb of the c abl gene within the 
intronic region, between exons b1 and a1.  dbl  gene which is involved in 
the gate keeping of cell division beyond the S-phase of the cell cycle is 
homologous to bcr gene, particularly its central part involved in 
translocation.  
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 The activity of GTP activating protein, p21, is present in the C-
terminus of the bcr. p21 belongs to the ras family of proteins that comes 
uder the family of GTP binding protiens107. Incontrast, some cases of 
CML develop abl-bcr fusion gene. This reciprocal hybrid gene is formed 
by interaction of p160bcr with the SH2 domain of abl gene.  This hybrid 
gene is formed on chromosome 9q+ while the characteristic Philadelphia 
gene is formed on chromosome 22q-. Some CML cases have active 
transcription of this hybrid gene108.  
 
 The  Philadelphia chromosome formed by reciprocal 
translocation is a short chromosome 22, a result of t(9; 22)(q34; q11). 
This translocation produces a fusion BCR/ABL gene. mRNA that is 
formed has breakpoint in the BCR gene in the 5.8-kb major breakpoint 
cluster region called as M-bcr. In contrast, breakpoints on 9th 
chromosome occur in the abl gene. As a result of t(9,22), all exons distal 
to the point of breakage within M-bcr in 3’ bcr-gene are completely 
removed and located again  to chromosome 9. Exons in 5’ bcr-gene 
comprising  bcr exons  1 and 2, including exon 3 or without exon 3 
remain on chromosome 22. The c-abl exons 2 (a2) through 11 are 
transposed to chromosome 22 and exons a1 and b1 may be added to it. 
During the mRNA formation process, the splicing acceptor site involved 
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in c-abl gene in exon a2 can skip splice donor sites in c-abl exons a1 and 
b1 to fuse with splice donor sites of the juxtaposed bcr.  Two  potential 
junctions are encoded depending on whether bcr exon 2 (b2) or bcr exon 
3 (b3) is joined to c-abl a2. The fusion transcripts formed are designated 
as b2a2 or b3a2 depending on bcr exon b3, absence or presence. The 
presence of b2a2  indicate the non existence of bcr exon 3 due to the 
mechansim of alternative splicing. They differ  in size and length by 75bp 
at the mRNA level and differ by 25 amino acids at the level of proteins. 
Both b2a2 and b3a2 have elevated tyrosine kinase activity, and both 
transcripts have same molecular weight of  210 kD (p210), and both of 
them can phosphorylate tyrosine residues on cellular proteins. The 
phosphorylation of tyrosine residues is similar to v-abl protein products 
phosphorylating activity.   
 
 The difference between p210 bcr-abl from the normal p145abl is 
that the end terminal of p210 bcr abl is substituted by bcr sequences.  The 
p210 bcr-abl can transform hematopoietic stem cells in vitro109 and this 
could be one of the many steps leading to leukemogenesis. The p210bcr-
abl fusion protein has the ability of making the progenitors and 
granulocytes survive longer by inhibiting the genetically programmed 
normal determinants of cell death. This causes expansion of the cells in 
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the leukemic clone. Due to alternate splicing in some patients, 
coexpression of both transcripts b2a2 and b3a2 has been reported110.  
 
 The breakpoints outside the M-bcr lead to various other 
rearrangements. The fusion protein of 210 KD encoded by BCR-ABL 
varies in kb, depending on breakpoint locations in the BCR gene  
between exons b2 and b3 or between exons b3 and b4 in a 3' or 5' gene 
rearrangement study. Depending on the breakpoint locations, two kinds 
of mRNA are created: b2a2 or b3a2. In most cases, cells have one of the 
two, b2a2 or b3a2 transcripts, but in 5-15% of cases alternative splicing 
results in the expression of two fusion transcripts too. The b3a2 transcript 
is larger by 75 bp.111  
 
 The fact that the p210 Bcr/Abl fusion protein can induce a CML-
like disease provides strong evidence for their fundamental causal role in 
human CML112. Differences in the site of BCR breakpoint and the types 
of BCR/ABL transcripts suggest that Subtypes of CML can be separated, 
with different prognosis and clinical course. An increasing number of 
studies have shown no clinical impact of the site of breakpoint, M-BCR, 
or the type of BCR/ABL transcript.113 
 
 Three breakpoint cluster regions are identified till date: major (M-
bcr), minor (m-bcr) and micro (mu-bcr). Maximum CML patients have a 
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p210BCR-ABL gene or Major-bcr, with mRNA transcripts being b3a2 
and/or a b2a2 junction.  
 
 The BCR breakpoint site can be classified according to the 
presence of the rearranged band seen in the digested DNA after 
hybridization. In a study, 29% of the patients expressed the b2a2 
transcript, whereas 62.3% expressed the b3a2 transcript. Both the b2a2 
and b3a2 types of transcript were found in 8.2% of the patients in a study 
of 62 patients. The median duration of CP for patients with transcripts 
b2a2 and b3a2 was 39 and 42 months respectively.  A statistically 
significant correlation between the two groups (b2a2 and b3a2) was 
observed in overall survival (p=0.0420). The patients with the b3a2 type 
of transcript survived significantly longer than the group expressing the 
b2a2 transcript. The longer duration of survival of the patients showing 
the b3a2 transcript expression may be caused by the less aggressive 
course of the accelerated or blastic phase. 114 
 
DETECTION OF GENE REARRANGEMENT IN CML: 
 The rearrangement of gene bcr-abl in CML cases which are ph+ 
leads to the production of mRNA transcripts of two different types, b2a2 
and b3a2. Inorder to find the the transcripts, the RNA is first separated 
from the leukemic cells followed by reverse transcription to cDNA and 
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finally subjected to PCR. The amplified PCR products is then confirmed 
via Southern Blotting after which probing is done or yet another round of 
PCR (nested PCR) is done. Another method of verification is by DNA 
SEQUENCING. The methods involved in RNA extraction, the various 
requisites for PCR(eg. Temperature, enzymes, oligonucleotide primer, 
polymerase enzymes, etc) both of which are involved in the studies of 
bcr-abl gene rearrangement varies from lab to lab. [110] Inkeeping with the 
method illustrated by the manufacterur GibcoBrl, RNA is extracted from 
the white cells with the help of trizol LS reagent. RT-PCR is done in one 
step with the help of Promega Access system, NB1+ and Abl3  happen to 
be the first primer pair which is applied in the starting round of PCR. This 
lads to amplification of the genetic material between bcr exon b1 and abl 
exon a3 of the fusion bcr-abl gene. The resultant PCR products that have 
been amplified are subsequently introduced to the next round of PCR also 
called nested PCR with 35 cycles.    
 
 B2A and CA3 are the primer pair set which is unbound to the first 
set (nested primer) and are meant for detecting b2a2 and b3a2 transcript. 
CA3 and A2 aplifies the abl region which is not translocated. Hence this 
serves as the abl control. This test permits the detection of one ph+ cell 
amidst 103 normal cells. Subjection to nested PCR increases the detection 
rate to 1 ph+  amidst 106 normal cells.         
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 Studies related to Bcr-abl gene rearrangement is of great use in 
making the diagnosis of CML. The drawback in cytogenetics is that the 
metaphase spread which is best for analysis is that may at times not be 
obtained. Yet another plus point over cytogenetics is that in conditions 
where bonemarrow is not available the test can be carried out with a 
peripheral blood sample for molecular analysis. This bcr-abl gene 
rearrangement studies can also be used to differentiate CML blast crisis 
from ALL. CML blast crisis will be ph+ bcr+, whereas ALL will be ph+ 
bcr-. This study will be of help in monitoring the course or progress of 
the disease. For eg. After BMT or  treatment with alpha interferon , by 
detecting Ph chromosome we can assess the minimal residual disease.  
 
MOLECULAR BASIS OF PH CHROMOSOME-POSITIVE 
ACUTE LEUKEMIA: 
 Point to be noted is that, in acute leukemia, Ph chromosome is 
linked not only with breakpoints within M – bcr(ph+ bcr+) rather this 
break can also be seen at 5’ upstream of M-bcr. However it mostly comes 
within the first intron of bcr gene chromosome 22. This area is named the 
minor breakpoint cluster region (m-bcr).  
 
 Due to the rearrangement occurring within m-bcr, the fusion of bcr 
– abl gene leads to the formation of 7.0kb mRNA. This is attributed to the 
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fusion of the first exon (e1) of the gene bcr with the second exon a2 of the 
gene c-abl. The ultimate product of translocation is 190KD protein, bcr-
abl with an increase in tyrosine kinase activity. It is found that p190 bcr-
abl has an effect that is more potent than p210 bcr-abl. 
 
 Those leukemias bearing ph+bcr- rearrangements of m-bcr indicate 
de-novo acute leukemia. Such ph+ acute leukemia can be biphenotypic or 
a hybrid of myeloid-lymphoid lineage. 
 
A) MYELOGENOUS  
 It has been reported tha the Ph chromosome is present in 1-2% of 
adult AML cases.when it comes to ph+ acute leukemia we encounter two 
varieties: one is CML presenting in myeloid blast crisis (Ph+ bcr+ AML) 
and the other is denovo AML(Ph+ bcr- AML)[52]  
 
 Facts that points to the diagnosis of CML presenting in myeloid 
blast crisis (Ph+ bcr+ AML) are as follows:  
 
i) Blast crisis can manifest within days after diagnosis of Ph+ 
CML is diagnosed. 
ii) Some cases showed features of additional cytogenetic 
abnormalities  comparable to CML blast crisis. 
iii) severe hepatosplenomegaly. 
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iv) Platelet counts are largely normal and there is intermittent 
increases of basophils. 
v) certain signs and symptoms like  weight loss, prolonged period 
of weakness. 
vi) Poor prognosis like CML in myeloid blast crisis.  
vii) when patient is in remission, the disease course appears like 
CML at chronic phase. 
viii) Rearrangement at the M-bcr on chromosome 22, production of 
bcr-abl  fusion gene and translation of p210 bcr-abl protein 
product, similar to CML resulting in the production of p210 
bcr-abl. 
 
Arguments in favour of de novo AML (Ph+ bcr- AML) are as follows:  
i) Additional chromosomal abnormalities are different from those 
seen in CML myeloid blast crisis.  
ii) The Ph chromosome is  associated with breaks outside the M-
bcr (at them-bcr) and a translation product of  p190 bcr-abl.  
 
B) LYMPHOCYTIC 
 Translocation t(9,22) is seen in 15-30% of adults with ALL and in 
3-5% of childhood ALL. The presence of the t(9,22) in ALL carries a 
poor prognosis. Two groups of Ph+ ALL  are reported by Molecular 
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studies. One is that CML itself presents in lymphoid blast crisis (Ph+ 
bcr+ ALL) and the other is de novo ALL (Ph+ bcr- ALL).  Some adults 
and few children with ALL have rearrangement within the M-bcr and 
production of p210 (Ph+ bcr+ ALL or lymphoid blast crisis of CML). At 
remission, patients may revert to CML, and are Ph+. Rearrangement not 
within the Mbcr region is seen in some adults and virtually in all children 
with ALL, that is at the m-bcr(p190 bcr-abl) with genotype Ph+ bcr- ALL 
or de novo ALL. In CML with lymphoid crisis there occurs remission, 
with  appearance of normal hemopoiesis.[52] 
 
SOUTHERN BLOTTING: 
 A gene fusion that is specific for a particular translocation can be 
analysed by Southern blotting and PCR. In Southern blotting, restriction 
enzymes that are sequence-specific cut the DNA and fragments are 
separated by agarose gel electrophoresis based on the size variation of the 
fragment recognized by a specific  probe for various fusions. 
 
RISK ANALYSIS IN CML: 
SOKAL SCORE: 
 The Sokal score117 is derivative of  813 patients diagnosed with 
chronic phase of CML from a multivariate analysis of survival of patients 
between 1962 and 1981. Either single-agent chemotherapy or  busulfan 
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treated cases are studied. % of blasts and spleen size were most strongly 
associated with survival. Formula and scoring (annexure 1). 
 
HASFORD SCORE: 
 The Hasford score also known as Euro score118 is a derivative   
from multivariate analysis of survival of early CML cases who were 
started on treatment between 1983 and 1994. Study included 981 patients 
with early CML. All cases studied were treated with only interferon 
alpha, or combination with another drug. The score was validated in a 
separate cohort of 322 patients. Formula and scoring:(annexure 2) 
 
EUTOS RISK SCORE: 
 The European Treatment and Outcome Study risk score for CML 
was derived from response of 2060 patients by multivariate analysis, who 
were treated with imatinib between 2002 and 2006. The score is 
applicable to cases before starting therapy, at the time of diagnosis 
itself.119 Formula and scoring (annexure 3). 
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AIMS AND OBJECTIVES 
 
1. To correlate  the following parameters: age, sex, clinical and 
haematological parameters of newly diagnosed CML patient  to the 
disease course and cytogenetic findings. 
2. To determine the frequency of  various chromosomal abnormalities 
in CML cases at the disease diagnosis.  
3. To determine the frequency of standard Philadelphia and variant 
translocation. 
4. To quantitatively assess the nature of expression of the fusion 
product- b2a2 and b3a2 transcripts in Ph+ CML. 
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MATERIALS AND METHODS 
 
 A total of 30 cases were taken into study. All thirty cases were 
confirmed to be Chronic Myeloid Leukemia by blood counts, peripheral 
smear, bone marrow aspiration, cytogenetics and molecular genetics.  
 
INCLUSION CRITERIA WERE:  
i) Newly diagnosed CML cases not started on any chemotherapy. 
 
Criteria for exclusion were:  
i) any signs of accelerated disease, i.e. more than 10% 
myeloblasts and promyelocytes in the peripheral blood,  
ii) prior treatment with any drugs such as busalfan, hydroxyurea, 
interferon, imatinib or nilotinib. 
 
 All 30 cases were evaluated with blood counts using a 5 part 
automated counter and verified manually with peripheral smear. 
Ultrasound abdomen and portal doppler was done at enrollment itself. 
The size of the spleen is assessed by real time b mode ultrasonogram 
performed in Institute of Radiology, Madras Medical College. Renal 
function test and liver fuction test was done in biochemistry lab. 
Coagulation profile (prothrombin time and activated partial 
thromboplastin time) was done in hematology laboratory. The bone 
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marrow aspirate was obtained from the patients and outsourced to Centre 
for Medical Genetics for cytogenetic analysis. Routine G-banding was 
done for karyotype analysis. Care was taken to see that bone marrow 
sample reaches the laboratory on the same day of collection. Peripheral 
blood from patients was sent for BCR-ABL qualitative analysis to SN 
GENE LAB,Surat.  
 
 Blood counts, serum chemistry, portal venous Doppler study, 
ultrasonogram of abdomen and coagulation profile were performed at 
enrollment, and blood counts  monthly until the patient is on followup. 
The small size of the sample is due to economic constraints. Qualitative 
RT-PCR for the BCR-ABL transcript was routinely performed for 
determining the type of transcript and fusion product.   
 
  All 30 cases were started on imatinib after initial diagnostic 
workup and quantitative BCR – ABL was performed to assess the major 
molecular response (MMR) in selected cases only due to economic 
constraints.  
 
MATERIALS FOR CYTOGENETIC STUDIES: 
 Cytogenetic study was performed in the Centre for Medical 
Genetics, Kilpauk, Chennai. 
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PRINCIPLE: 
 Bone marrow samples which contain spontaneously dividing cells 
are cultured  short term without mitogen. Chromosome analysis of the 
dividing cells is useful in the diagnosis of malignancy and in the 
classification of hematological malignancies. 
 
METHODOLOGY FOR CYTOGENETIC STUDIES: 
A. SPECIMEN ACCESSIONING 
 Upon receipt in the laboratory, the sample is accessioned. 
Accessioning includes  checking the patient’s name, recording the 
volume and condition of the sample,  and recording the time and date 
that the sample is received. 
 
B. SPECIMEN REQUIREMENTS 
1. ~2 mL of first or at least second tap marrow specimen 
freshly drawn into a sodium heparin vacutainer or syringe 
coated with heparin.  
2. The marrow should have sufficient spicules. 
 
C.  REAGENTS AND MATERIALS (ANNEXURE IV) 
D. SETUP 
 Bone marrow and leukemic blood specimens are setup according to 
the reason for referral and the age of the patient. 
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1. The specimens are setup as overnight (ON) / Two day (2d). 
 
2. WBC’s are to be checked in house for the following circumstances: 
a) The specimen received is from a pediatric patient. 
b) The specimen received looks very thick or thin. If the specimen is 
inadequate, setup an ON culture only 
c) The specimen received has been shipped form clients with     great 
shipping  distances or delayed arrival. 
d) The specimen received has a very high or low WBC indicated on 
the requisition form. 
 
3. Use the WBC count to [106/mL] determine the volume of specimen 
needed to seed a culture. 
 
4. Setup the following tubes and incubate at 37ºC with the caps loose. 
Label, T-25 culture flask with the patient’s name, accession number, 
and the date received.   
 a)   1 day tube / 2 day tube 
 
Specimen depending on the count. 
 b)   Repeat patients 
 
If there is adequate volume specimen, setup overnight culture. 
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 c)  If there is an inadequate specimen volume, setup at least one  
  ON culture. Use your judgment for additional cultures. 
 d)  If the WBC is higher or lower, use your own judgement. 
 
F.   HARVESTING 
1) Add 40 µL of Colcemid to each 1 day/2 day culture early the 
next working day (~ 5:30 AM) and incubate at 37ºC for 1 hour. 
2) Decant specimens in flasks to labeled centrifuge tubes. 
3) Centrifuge tubes at 1100 rpm for 7 minutes. 
4) Pour off the supernatant; gently resuspend the cells in 10 mL of 
freshly mixed hypotonic solution (8 mL of 0.56% KCL stock 
solution and 2 mL of distilled water) and incubate at 37ºC for 
15-17 minutes. 
5) Add 1 mL of fixative (3:1, Methanol to Acetic Acid); centrifuge 
at 1100 rpm for 7 minutes. 
6) Pour off the supernatant; gently resuspend the cell pellet; add 10 
mL of fresh fixative; let sit for 15 minutes. 
7) Pour off the supernatant; gently resuspend the pellet in fresh 
fixative; centrifuge for 7 minutes. 
8) Pour off the supernatant; gently resuspend the pellet in a 
quantity of fix to make a reasonable cell suspension for 
preparing slides 
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9) Drop the cell suspension on a microscope slide; evaluate on a 
phase microscope; make two more slides. 
10) Bake slides at 90ºC for 1 hour. Follow the routine banding 
procedure.  
 
G.ANALYSIS  
1) Analyze 20 metaphases for each specimen. If a sufficient number 
of metaphases are not available, analyze as many as possible. 
Analysis includes,  identifying members of each group, checking 
for all bands in both  homologues, identifying sex chromosomes 
and counting total chromosome number. 
 
2) Select three metaphases for karyogramming if all metaphases are 
identified as normal. 
 
3) If the metaphases are not analyzable because of several complex 
abnormalities and / or several unidentifiable markers, count the 
total chromosomes and  select metaphases to be imaged for 
review. 
 
4) If the case is abnormal, select two metaphases from each abnormal 
clone for karyogramming. 
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MOLECULAR ANALYSIS: 
 All samples were tested in SN gene lab Surat, India.  Whole buffy-
coat cells were used. RNA extraction, RT-PCR, and real-time quantitative 
PCR were performed according to WHO recommendations. Real-time 
quantitative PCR was performed on an ABI PRISM 7700 sequence 
detector (Perkin Elmer). ABL was used as housekeeping gene to correct 
differences in RNA quality and/or RT efficacy. BCR-ABL and ABL 
plasmid dilutions (Ipsogen) were used as standards. The final results were 
calculated as the ratios of BCR-ABL to ABL and are expressed as 
percentages. All experiments were performed in duplicate, and the results 
are expressed as the percent ratio to ABL. The BCR-ABL:ABL ratios 
were further multiplied by the conversion factor of the Bologna 
laboratory to set the results on an international scale. Qualitative BCR-
ABL was assessed by similar RT-PCR. RNA extracted,  using many 
primers, specific for different transcripts of various sizes, were amplified 
by PCR. This PCR product is made to run on agarose gel and 
electrophoresed against gel matrix containing known probes of various 
BCR-ABL fusion transcripts. All samples were tested for following 
transcrips: b2a2 (p210), b3a2 (p210). 
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METHODOLOGY FOR MOLECULAR STUDIES: 
 Reagents and consumables used in PCR must be sterile. For 
molecular studies autoclaving of all test tubes, pipette tips and containers 
should be done to prevent contamination. Wearing gloves and necessary 
sterile precautions should be taken. RNA extraction and  reagents 
disposal should be done with a new pair of gloves. RNA extraction and 
PCR amplification steps should be performed in separate rooms.  
 
EXTRACTION OF WHITE CELLS: 
a) 1 ml  of whole blood is diluted with 0.9% saline of about 1 ml. 
b) diluted blood should be layered on top of  ficoll-paque of 1ml in a 
15 ml conical centrifuge  tube which is sterile.  
c) a refrigerated centrifuge is used to centrifuge at 40 c for 25 minutes 
at a rate of 2500 rpm. 
d) white cell layer should be aspirated into a 15 ml sterile centrifuge 
tube with 0.9% saline of about 10ml.  
e) a refrigerated centrifuge is used to centrifuge at 40 c for 25 minutes 
at a rate of 1500 rpm. 
f) supernatent should be discarded and cells are resuspened in 10 ml 
of 0.9% saline 
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g) a refrigerated centrifuge is used to centrifuge at 40 c for 25 minutes 
at a rate of 1500 rpm.  
h) supernatent should be discarded and cells are resuspended in 10 ml 
of 0.9% saline 
a. Aliquot of  1 ml each should be added  into cryovial and                                
store frozen at –700 C  
 
RNA EXTRACTION 
a) frozen white cells of amount of one cryovial should be thawed to 
room temperature. 
b) Into an ependorf tube with a capacity of 1.5ml,  containing 750 ul  
trizol, 250 ul of the  white cells are added.  
c) allow to stand for 5 minutes 
d) 200 ul of separating reagent is added to the BCP phase.  
e) This mixture should be shaked vigorously for 40 seconds and 
allowed to stand for 15 minutes. 
f) this mixture is again centrifuged at 13,600 rpm in a       microfuge 
for 15  minutes. 
g) after centrifugation the mixture is separated into 2 phases, a pink 
coloured  lower phase and aqueous upper phase. 
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h) Into an ependorf tube with a capacity of 1.5ml, containing 500 ul 
isopropanol, the upper phase is added. 
i) allow the mixture to stand for 10 minutes after mixing it. 
j) again the mixture is centrifuged at 13,600 rpm for 10  minutes 
k) discard the supernatent and the RNA pellet is resuspend in 1000 ul 
of 70% ethanol 
l) now the mixture is again centrifuged for 10  minutes  at 13,600 
rpm. 
m) discard the supernatent  and dry the RNA. But the RNA should not 
be dried completely as this would make the RNA difficult to 
dissolve. 
n) RNA is dissolved in 50ul – 200ul RNAse DNAse free water. 
o) RNA is heated for 10-15 minutes in a water bath at 55-600C.  
p) this RNA is stored at –700 C. 
 
ONE STEP  RT-PCR: 
a) name a tube as M and thaw it. 
b) to tube M, 0.5 ul AMV and 0.5 ul Tfl is added. 
c) to this tube M 2.5 ul RNA is added. 
d) this tube M is incubated in a thermal cycler for: 
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i. at 480C for 46 minutes and this is followed by 2 
minutes incubation at  940C. 
ii.  following which 35 cycles are run with each cycle  
consisting of 3 set of temperatures: at 640 C for 1 min, 
740 c for  min.  
iii. a final extension step, 730 C for 10 minutes 
 
e) A control  tube M with AMV and Tfl but without RNA is 
incubated in the above reaction in the thermal cycler. 
 
NESTED PCR: 
a) Take two tubes A and B and thaw them.  
b) 1 ul of material is taken from the PCR product of each tube M and 
added to tubes A and B. 
c) both tubes A and B are incubated in a thermal cycler at temperature 
of:  
i. 960 C for 2 min 
ii. followed by 35 cycles, with each of the cycle consisting of 3 
temperatures of  960c for 1 min, at 640 C for 1 min, 720 C for 
1 min and 
iii. finally an extension step of 730 C for 10 minutes 
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d) these nested PCR products in tubes A and B are stored at –700C if 
they are to be electrophoresed later. 
 
AGAROSE GEL ELECTROPHORESIS 
a) 2% agarose gel is prepared  by dissolving agarose of 0.8g in 40 ml 
in TBE buffer in a microwave oven. 
b) ethidium bromide of 1ul is added to (a). 
c) the agarose gel that is melted is poured into a tray with a comb to 
make the sampe wells (Easy-Cast) 
d) after the solidification of  agarose occurs, the comb is removed and 
the gel in a refrigerated at 40 C for further use. The gel should not 
be kept for more than a day. 
e) 1 ul of the nested PCR product together with l ul of loading dye 
and 6 ul of distilled water is put on a piece of paraffin. This is 
mixed  and loaded into a well on the agarose gel card. 
f) the molecular marker containing mixtures of 1 ul of 100bp ladder 
along with 10 ul of distilled water and 2 ul of  loading dye on a 
piece of paraffin is mixed and 6 ul is loaded at the opposite ends of 
the wells.  
g) the electrophoresis is run at 130V for an hour or until the dye 
reaches three-quarter of its way over the gel. 
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Photography 
a) the gel is now viewed under UV light using a transilluminator. 
b) the gel is photographed using the camera system. 
c) Interpretation of results is based on the position of the bands  from 
the wells containing samples in tubes A and B, with the 100 bp 
ladder as a molecular marker.   
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OBSERVATION AND RESULTS 
 A total of 157 leukemic patients attended outpatient Department of 
Hematology from january 2013 to august 2014. Of   157   cases, 48 cases 
were diagnosed Chronic Myeloid Leukemia. Of  48  CML patients, 30 
patients of CML were taken into study. 8 cases were lost for follow up. In 
10 cases cytogenitics at diagnosis was not done.       
  
TABLE 1: Parameters of 30 CML cases involved in study 
 
S.No AGE SEX KARYOTYPE
1 45 F 46xx,t(9,22)(q34;q11.2)
2 44 M 46xy,t(9,22)(q34;q11.2)
3 45 M 46xy,t(9,22)(q34;q11.2)[3]/48,idem,+8,inv(12),+21[22] 
4 39 M 46xy,t(9,22)(q34;q11.2)
5 43 M 46xy,t(9,22)(q34;q11.2)
6 65 F 46xx,t(9,22)(q34;q11.2)
7 49 M 46xy,t(9,22)(q34;q11.2)
8 45 F 46xx,t(9,22)(q34;q11.2)
9 46 M 46xy,t(9,22)[8]/49xy,idem,+8,+19,t(9,22)[18]
10 24 F 46xx
11 24 M 46xy,t(9,22)(q34;q11.2)
12 36 M 46xy,t(9,22)(q34;q11.2)
13 49 M 46xy,t(9,22)[14]/ 47, idem, +der(22) t(9,22)[22]
14 26 M 46xy,t(9,22)(q34;q11.2)
15 52 M 46xy,t(9,22)(q34;q11.2)
16 60 M 46xy,t(9,22)(q34;q11.2)
17 60 F 46xx,t(9,22)(q34;q11.2)
18 45 m 46xy,t(3,6,9,22)(p13;p21;q34;q11.2)[25]
19 35 m 46xy,t(9,22)(q34;q11.2)
20 24 M 46xy,(9,22)(q34;q11.2)
21 41 M 46xy,(9,22)(q34;q11.2)
22 24 M 46xy,(9,22)(q34;q11.2)
23 24 M 46xy,t(9,22)(q34;q11.2)[3]/45x, idem, -y[22]
24 57 F 46xx,t(9,22)(q34;q11.2)
25 46 F 46xx,t(9,22)(q34;q11.2)
26 43 M 46xx,t(9,22)(q34;q11.2)
27 30 M 46xy,t(9,22)(q34;q11.2)
28 29 M 46xy,t(9,22)(q34;q11.2)
29 40 F 46xx,-1,der(6)t(1,6)t(6,13),der(7)t(1,7),t(9,22),del(10)+mar[23]
30 29 f 46xx,t(9,22)(q34;q11.2)
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 30 cases of newly diagnosed CML, not started on any treatment 
was included into study. Non-modifiable risk factors, clinical parameters, 
karyotypes observed were compared with each other. Risk analysis was 
done using Sokal, Hasford and EUTOS scoring systems. 
 
 23 cases had only t(9,22)(q34,11.2), 1 case had variant 
translocation, 5 cases had major and minor additional chromosomal 
abnormality and  case had normal karyogram inspite of BCR-ABL gene 
being positive. 27 of 30 cases showed only abberant clone. Only 3 cases 
showed normal metaphases (46xx and 46xy) in parallel to aberrant clone. 
In 3 of 4 patients with major route ACA, complex aberrant karyotypes 
with 3 or more chromosomal alterations were detected. 
 
Frequency of expression of various karyotypes: 
 76.66% (23 cases) presented with only Philadelphia translocation 
t(9,22). 20% (6 cases) had additional chromosomal abnormalities in 
addition to Philadelphia chromosome. These ACA observed were 6.7% 
(2 cases) with extra Philadelphia chromosome, 3.33%(1 case) with 
trisomy 8, 3.33%(1 case) with trisomy 8 and trisomy 19, 3.33%(1 case) 
with –y ond 3.33% with other rare abnormalities like der(6), t(1,6), 
t(6,13), der(7), t(1,7), del(10), +mar, 3.33% (only 1 case) had complex 
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variant translocation involving chromosomes 3, 6, 9 and 12 and 3.33% (1 
case have normal karyotype without expressing t(9,22)) but BCR-ABL+ 
and case is included under cases with t(9,22) itself for statistical purpose. 
To confirm the karyotypic abnormality FISH was planned but withdrawn 
due to financial constraints. 
 
Table 2 : Frequency of expression of various Karyotypes 
Karyotypes frequency % 
Ph only 23 76.66% 
Ph -, BCR – ABL + 1 3.33% 
Additional 
chromosomes 
• extra ph 
• + 8 
• + 8, + 19 
• - Y 
• Variant    
 translocation 
 
5 
2 
1 
1 
1 
1 
 
16.67% 
6.7% 
3.33% 
3.33% 
3.33% 
3.33% 
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 Majority of the cases have t(9,22) involving locus 34, 11.2 of long 
arm. Among the additional chromosomal abnormality extra Philadelphia 
chromosome and trisomy 8 was the most common abnormality observed. 
Among trisomy 8, one patient had additional trisomy 19. Other 
abnormalities have equal incidence. Frequency of various karyotype 
expression is shown in table 2. 
 
Age distribution: 
 Majority of the cases, 46.66% (14 cases) presented in the age group 
of 40 – 60 years. 43.33% (13 cases) presented in the age group of less 
than 40 years and only 10%(3 cases)  presented in >60 years of age. 
Table 4 shows age distribution of cases. Thus majority presented in the 
76.66%
6.70%
3.33%
3.33%
3.33% 3.33%
FREQUENCY OF VARIOUS KARYOTYPES
ph
extra ph
trisomy 8
trisomy8,19
del y
variant t
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age group of 40-60 years. Among 46.6% in the age group of 40-60 years, 
71.42% have translocation 9,22 only and 21.42% have additional 
chromosomal abnormalities. In <40 years age group, 84.16% have t(9,22) 
and only 15.38% have additional chromosomal abnormalities. Thus 
additional chromosomal abnormalities were observed maximally in the 
age group of 40-60 years only. Since very few number of cases were 
registered >60 years, significant correlation of age with chromosomal 
abnormality cannot be arrived at. Although no ACA were detected above 
60 years, ACA above 60 years cannot be excluded altogether. 
 
        Table 3 : Age distribution of various karyotypic abnormality 
 
 
 
Age range Ph+ Ph+addi 
chr.abn. Variant t 
% total in 
each age 
group 
< 40 Years 11 (84.61%) 2 (15.38%) 0% 43.33% 
40 – 60 
Years 10 (71.42%) 3 (21.42%) 1(7.14%) 46.66% 
> 60 Years 3(100%) 0% 0% 10.00% 
  
 
Sex distribution:            
 A total of 21 males and 9 females were analysed randomly. Table 5  
shows sex distribution among various karyotypes. On evaluating the sex 
distribution of karyotypic abnormalities, 70% (21 cases) were males and 
30% (9 cases) were females. Hence, disease was
more commonly among males than females. 
 
 
0
2
4
6
8
10
12
<40 yrs
AGE DISTRIBUTION  OF VARIOUS KARYOTYPES
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 found to be associated 
 
 
40-60 yrs >60 yrs
ph ACA variant t
 
 Table 4 : 
sex 
Males (69.56%)
Females (33.33%)
 
 
 
0
2
4
6
8
10
12
14
16
ph
SEX DISTRIBUTION AMONG KARYOTYPES
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Sex distribution among various karyotypes
Ph+ Ph+ addi 
chr.abn. Variant t
16 
 
4 
(80%) 
1 
(100%) 
8 
 
1 
(20%) 0 
 
ACA VARIANT T
MALES FEMALES
 
 
Total % 
of each 
sexes 
21 
(70%) 
9 
(30%) 
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 Among 76.66% with Philadelphia translocation 69.56% were 
males and 33.33% were females. And among 20% with additional 
chromosomal abnormalities, 80% were males and 20% were females. In 
view of single case with variant translocation, it is not possible to 
consider the value as statistically significant.                       
 
Spleen size and karyotype abnormalities: 
 All 30 cases had splenomegaly ranging from moderate to massive 
degree. None of them had mild splenomegaly. 76.66% (23 cases) had 
moderate splenomegaly between 11-20cm and 23.33% (7 cases) had 
massive splenomegaly of >20cm. table 5 shows the degree of 
splenomegaly and karyotypic abnormality.  
 
Table 5: Data showing severity of spleen size  
with karyotype frequency 
 
Spleen size Ph+ Ph+addi 
chr.abn. Variant t Total 
11-20 cm 21 (91.30%) 1 (4.34%) 1 (4.34%) 23 
>20 cm 3 (42.86%) 4 (57.14%) - 7 
 
  
 
 Comparing the spleen size between those with Philadelphia only 
and those with additional chromosomal abnormalities, 57.14% of those 
with additional chromosomal abnormalities had massive splenomegaly 
compared to 42.86% of them with Philadelphia and massive 
splenomegaly. 
 
Leucocytosis and chromosomal abnormality:
      Taking total leucocyte count of more than 200,000 into consideration 
3 patients (75%) out of 4 with ACA
compared to 15 patients (
presence of leucocytosis of more than 200000
prognosis. 
 
ph + additional chromosomal abnormality
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 have leucocytosis of >2lakhs when 
57.69%) out of 44 with non-ACA.  H
/dl is associated with poor 
 
57.14%
8.68%
% OF MASSIVE SPLENOMEGALY
 
ence the 
t(9.22)
  
89 
 
Table 6 : Comparison of TLC among AC and non-ACA 
  
Platelet Count and Abnormal Karyotypes: 
 Generally CML is characterised by thrombocytosis. Abnormally 
high platelet counts of more than 600,000/dl is found in 50% of patients 
with ACA while only 15.38% of patients with non-ACA have 
thrombocytosis. So thrombocytosis of more than 600,000/dl is associated 
with adverse outcome. 
 
 Also only one patient had thrombocytopenia and that to with 
abnormal ACA with two cell lines, one cell line with standard 
Philadelphia and other cell line with Philadelphia, trisomy 8, inversion 12 
and trisomy 21 in 22 metaphases. 
 
Table 7: Comparison of platelet count among ACA and non-ACA 
Platelet count > 600,000/dl < 600,000/dl 
ACA 2 (50%) 2 (50%) 
NON-ACA 4 (15.38%) 22 (74.21%) 
 
TLC > 200,000/dl < 200,000/dl 
ACA 3 (75%) 1 (25%) 
NON-ACA 15 (57.69%) 11 (42.31%) 
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PT and aPTT in CML: 
 3 of 30 cases had abnormally prolonged prothrombin time of >20 
sec and 16 of 30 cases had abnormally prolonged prothrombin time of 
>38sec. This abnormal prolongation can be attributed to hepatic 
compromise and/or acquired inhibitors and further studies have to be 
done to find out the cause. There was no significant prolongation in cases 
with ACA as compared with standard Philadelphia translocation. 
 
Table 8 : Characteristics of patients with major route ACA 
No.acc. 
to 
table1 
Karyotypes 
(short) in 
addition to 
t(9,22) 
% of 
metapha
ses with 
ACA 
Follow 
up 
period 
(mon) 
Course 
3 +8, inv(12), +21 88% 4 
Thrombocytopenia, 
renal compromise 
necessitating dialysis 
9 +8, +19, extra ph 72% 18 
Unexplained 
leucopenia and 
thrombocytopenia 
warranting stoppage of 
imatinib 
13 +der22 extra ph 88% 18 No progress in disease. On nilotinib from day1 
29 
-1, der(6)t(1,6) 
t(6,13), 
der(7)t(1,7), del 
10, + mar 
92% 18 
Acceleration after 1 
year so dose of 
imatinib is increased. 
Develops syptoms 
pertaining to 
mastocytosis 
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Risk Categorization of Cases:                                                                        
 Hasford and Sokal index scoring systems are available to predict 
survival duration of CML patients on imatinib therapy. 
 
Sokal Scoring System: 
 Sokal score is calculated by taking into account the following 
parameters: age of the patient, spleen size, platelet count and blast% in 
peripheral blood. Table 6 shows the sokal scoring for all cases according  
to the karyotype expressed. 
 
Table 9 : Sokal Score 
Karyotype Low Intermediate High 
Ph only 1 (4.30%) 7 (30.43%) 16 (66.66%) 
Ph+ additional 
chromosomal 
abnomality 
- 2 (33.33%) 4 (66.66%) 
 
 According to the sokal scoring, 65.21% (15 cases) with 
Philadelphia translocation and 66.66% (4 cases) with additional 
chromosome abnormality were found to have high risk. 
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Hasford scoring : 
 Hasford score is evaluated with following parameters: age, spleen 
size, platelet count, peripheral blood blast%, eosinophil% and basophil%. 
Table 7 shows hasford score between Philadelphia and abnormal 
karyotypes. 
 
Table 10 : Hasford Score 
Karyotype Low Intermediate High 
Ph only - 19 (79.16%) 5 (21.73%) 
Ph+ additional 
chromosomal 
abnormality 
- 5 (80.00%) 1 (20.00%) 
 
 Hasford scoring shows 80% of those with additional chromosomal 
abnormality and 78.26% with Philadelphia translocation was found to 
have intermediate risk. 21.73% of cases with Philadelphia translocation 
have high risk and 20%with additional chromosome abnormality have 
high risk. 
 
EUTOS scoring: 
 Parameters taken into scoring are: Basophil% and spleen size.  
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Table 11 : EUTOS Score 
 
Karyotype Low Intermediate 
Ph 5 (21.73%) 19 (79.16%) 
Ph+ Additional 
Chromosomal 
Abnormality 
- 6 (100.00%) 
 
 Eutos scoring shows 100% high risk  for those cases with 
additional chromosomal abnormality and only 78.26% of those with 
Philadelphia have high risk. 
    
Table 12 : Comparison of Hasford and Sokal scoring system 
Score Sokal Hasford 
Low 1 0 
Intermediate 9 24 
High 20 6 
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Table 13 : Comparison of scoring system in cases with ACA 
Karyotype Category Sokal Hasford EUTOS 
PH+additional 
chr abn. 
intermediate 2 5 0 
high 4 1 6 
 
 In 6 cases with Philadelphia translocation with additional 
chromosomal abnormality,2 cases were  classified as intermediate risk 
and 4 cases were classified as high risk by Sokal, 5 cases as intermediate 
risk and 1 case with high risk by Hasford and all 6 cases as high risk by 
EUTOS.   
 
 Thus risk scoring was found to have no significance in this study. 
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DISCUSSION 
 
 CML accounts for 20% of all types of leukemia. 30 cases were 
included into the study and completely investigated with complete blood 
counts, cytogenetic analysis and bcr-abl qualitative assay. 
 
 The incidence of Ph+ CML in patients was found to be 76.6%, 
compared to literature, which reports 85% - 95% (Cartwright et al,1992). 
According to Block et al,1999, 10 – 20% of  Ph+ CML patients have 
ACA at diagnosis. In the current study 13.33% of Ph+ CML patients have 
ACA. 
 
 Redaelli, Bell, Casagrande et al, stated the common age group of 
presentation of CML to be 40 – 60 years. Our study also confirms the 
common age group affected to be 40 – 60 years. 
 
 Among sexes, males are predominantly affected than females, 
according to Wintrobe, Hasenbush 1939 and David G Savage et al,1996, 
which reconciles with our study. 
 
 57.14% with ACA have massive splenomegaly compared to 
42.86% of Ph+ CML with massive splenomegaly.  
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 The most significant observation we found in the study was the 
negative impact of major route ACA from the time of diagnosis to the 
duration of progress free survival (PFS) and MMR. In patients with ACA, 
though the  observation period was kept to a minimum of 36 months, it 
showed a worse outcome which was significant and meaningful, inspite 
of the fact that only a small number of 5 patients had ACA.   
 
According to Fabarius et al, all other additional cytogenetic 
findings at diagnosis (ie, variant translocation, minor ACA) had no 
recognizable impact on prognosis. In our study, 1 case with complex 
variant translocation had no progress in disease course and the patient is 
doing well with nilotinib from the start. 
 
 According to Haferlach and Fabarius et al 2011, trisomy 8 was the 
most common chromosomal abnormality presenting in combination with 
various chromosomal abnormalities, followed next by isochromosome 
(17)(q) and extra Ph chromosome. 
 
 Our study also showed the most common additional chromosomal 
aberrations presenting at the time of diagnosis to be trisomy 8 and extra 
Ph. 
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            The study also states that median age of patients with ACA was 
lower than that of the other groups. But in our study the median age for 
patients with ACA was 38.5%.  
 
 According to Cortes, Talpaz et al, only major route ACA had 
prognostic impact, not minor route ACA. Major route ACA presenting as 
complex cytogenetic aberrations involving three or more chromosomes at 
the time of diagnosis showed poor prognosis. The study also shows that 5 
of 6 patients had progression of disease from chronic to accelerated 
phase, thereby decreasing PFS period. On the other hand, patients with 
minor route ACA had no significant impact on PFS. 
 
 In our study of 4 patients with major route ACA, all 4 have 
complex cytogenetic aberrations involving 3 or more chromosomes with 
median age of presentation being 43.33% and most commonly affecting 
males. In accordance with literature, most common abnormality was 
found to be trisomy 8 and extra Philadelphia.  
 
 In patients with ACA, it was found that leucocytosis of more than 
200x109/l in 75% and thrombocytosis of more than 600x109/l in 50% as 
against 57.69% and 15.38% in non-ACA was recorded which goes 
handinhand with literature by David G Savage et al,1996 who also shows 
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patients with ACA are likely to present with greater degrees of 
leucocytosis and anaemia. 
 
 Rowe et al, 1983 and Mason et al,1974 showed that patients with 
additional chromosomal aberrations have greater degrees of 
thrombocytosis when compared to patients with standard Philadelphia 
translocation. 
 
 On assessing the disease course in patients with chromosomal 
abnormality other than standard Philadelphia translocation, all additional 
cytogenetic abnormality at diagnosis including variant translocation, -y , 
but not major route ACA, had no impact on prognosis. Fabarius et 
al,2011 also derived at similar results. In our study, 1 case with complex 
variant translocation had no progress in disease course and the patient is 
doing well with imatinib from the start. Also our patient with –y showed  
similar disease course as patients who harbour standard t(9,22) according 
to the report of Ei-Zimaty et al 2004 and Marzocchi et al 2011. 
 
 Merlin et al,1996 found that the percentage of metaphases involved 
by ACA has dependence on nature of cytogenetic aberration. But this was 
disproved by  Fabarius et al,2011 who  reported that 59% of median 
metaphases are affected by major-route ACA, while only 85% of 
metaphases are affected by minor-route ACA. Hence the impact produced 
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by cytogenetic aberrations on the disease course is independent of the 
percentage of metaphases affected. In current study the median 
percentage of metaphases affected in major route ACA was found to be 
85% and median metaphases affected in minor ACA was found to be 
94% but these 94% affected metaphases have no bearing on prognosis 
thus proving the reports of Fabarius et al that impact of cytogenetic 
aberrations depends on the type of ACA independently of the percentage 
of metaphases affected. 
 
 In the past since all cytogenetic aberrations including major-route 
ACA, variant translocation, -Y, other minor-route ACA are evaluated as a 
whole, no prognostic impact can be detected. 
 
 We analysed the duration of PFS comparing between groups with 
only t(9;22), variant t, -Y, and major and minor ACA. After an average  
observation period of 13 months, the median times to PFS was 12 months 
for t(9,22), 12 months for t(v,22) and 10 months for –Y. This shows that 
there was no significant difference in the duration of PFS among those 
with minor ACA, whereas the duration of PFS was further reduced to 6 
months in cases with major ACA. Although the sample size is too small 
and follow up period is short, PFS was significantly reduced in patients 
with major ACA which cannot be deglected altogether. Fabarius et al 
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reported, the 5-year PFS of standard t(9;22) was 90%, for t(v;22) it was 
81%,for –Y it was 88%, for minor-route ACA as 96% and for major-
route ACA as 50% (P <.001) and the 5-year overall survival was 92%, 
87%, 91%, 96%, and 53%  with P vaiue < .001 respectively. Thus he 
concluded that Variant t and deletion Y had no significant influence on 
PFS or OS. 
 
 Comparing the survival and disease course between patients with 
ACA and non ACA, 24 of the 24 patients with t(9,22) and 2 of 2 patients 
with minor-route ACA were still alive, whereas 1 of 4 patients with 
major-route ACA, who had trisomy 8 in addition to trisomy 19 and extra 
Ph had persistent pancytopenia warranting stoppage of imatinib and he 
developed severe leucopenia and scummbed to sepsis. Other patient with 
trisomy 8 in addition to trisomy 21 and inversion 12 had severe renal 
compromise warranting dialysis. The other patient with translocation 
involving chromosome 1, 6, 7 and deletion 1, 10 went in for acceleration 
after  a period of 6 months of treatment with imatibib who attained 
remission and now doing better with increased dosage of imatinib. And 
the patient with derivative 22 along with t(9,22) is doing better with 
nilotinib from the start. Thus major route ACA were found to have poor 
prognosis and as reported by Kantarjjian et al, the chromosomal 
aberrations are non-random. 
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 The feature of nonrandom association of chromosomal aberrations 
associated with survival and disease progression is seen in other cancers 
which is considered as the principle probably for maintanence of 
carcinogenesis. (Fabarius and Willer et al 2002). Although an adverse 
progression is associated with more than one chromosomal abnormality. 
Second Ph chromosome, isochromosome(17)(q10) and   trisomy 8 which 
has unfavourable prognosis. 
         According to literature patients with CML are more prone to 
develop systemic mastocytosis and patients with systemic mastocytosis 
have trisomy 8, trisomy 9 and deletions of chromosome 1,7,9 and 11. Our 
patient with ACA had mean basophil count of 30 with symptoms of 
severe uncontrolled itching and mastocytosis with one patient harbouring 
trisomy 8 and other patient had abnormalities involving chromosome 1 
and 7, suggesting that these patients are more susceptible to evolve into 
systemic mastocytosis and finally basophilic leukemia for which 
monitoring should be done appropriately. 
 
 At diagnosis the patients with additional cytogenetic findings is 
20% and that of variant translocations is 3.33%, ACA is 9.7% and -Y is 
3.3%  which remains within the range of published data. 
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 At diagnosis, though the patients with major route ACA is small at 
about  13.33%, but still its impact on prognosis is evident. 
 
 We conclude that the analysis of presence of ACA at diagnosis is 
very essential in CML since the presentation is heterogeneous. Compared 
with other patients, those with major route ACA had poor prognosis and 
these cases require close monitoring and early intervention by stem cell 
transplant. 
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SUMMARY 
 
 CML accounts for 20% of all leukemias. >90% of patients present 
in chronic phase although 95% of those presenting in chronic phase of 
CML have reciprocal translocation involving chromosomes  and 22, the 
remaining 5-6% cases show additional chromosomal abnormalities at the 
time of diagnosis. These ACA were divided into major ACA, minor ACA 
and variant translocations. The significance of cytogenetic analysis at the 
time of diagnosis in patients with CML is the negative prognostic impact 
that they impart on the disease course and survival.  
 
 In this present study of 30 cases of CML, 6 of them had abnormal 
cytogenetics in addition to standard Philadelphia translocation.of the 6 
cases, 4 had major ACA while 2 had variant translocation and deletion Y. 
cases with major ACA were found to have leucocytosis of >2 lakhs, 
thrombocytosis of >6 lakhs and mean basophil count of 30 in the bone 
marrow sampling with the most frequent cytogenetic abnormality behind 
trisomy 8 and extra Philadelphia chromosome. 
 
 The duration of progress free survival in patients with major route 
ACA was found to be reduced significantly to a duration of 4 months as 
against patients with minor ACA and t(9,22), where duration of progress 
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free survival is very much prolonged with an average of 15 months and 
none of the patients went into acceleration in the entire observation 
period.  
 
 Thus we conclude that cytogenetic analysis at the time of diagnosis 
carries prognostic significance to the disease and hence it should be 
carried out on all cases irrespective of the phase of presentation. Also the 
presence of major ACA has poor prognosis. 
 
 Though the role of bone marrow biopsy and bcr abl gene 
transcripts are not included in the study, further studies may help in 
analysing their significance.  
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CONCLUSION 
 
• All cases of CML should be evaluated with cytogenetics as a part of 
initial diagnostic workup itself. 
 
• This helps in categorising the patients into various risk groups based 
on the presence or absence of Additional Chromosomal Abnormality 
(ACA) and knowing the type of ACA, thereby deciding the mode of 
treatment to be given and the nature of care to be delivered to these 
patients. 
 
• Major Additional Chromosomal Abnormality (ACA) has poor 
prognosis and most common ACA is trisomy 8 and Extra 
Philadelphia.  
 
• The duration of progress free survival in patients with major route 
ACA was found to be reduced significantly to a duration of 4 months 
as against other patients. 
 
• Depending on the type of cytogenetic abnormality and the prognostic 
impact of abnormality, these cases require close monitoring and early 
intervention by stem cell transplant. 
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ANNEXURE 1 
 
SOKAL SCORING: 
 
The score, which is a hazard ratio, is calculated using the following 
formula:  
 
exp (0.0116 x (age [years] – 43.4)) + (0.0345 x (spleen size [cm] – 7.51) 
+ (0.188 x ((platelets [109/L]/700)^2 – 0.563)) + (0.0887 x (blasts [%] – 
2.10)).  
 
 
Sokal et al proposed three risk groups:  
Low-Risk     (score < 0.8, 39% of patients),  
Intermediate-Risk  (score 0.8 - 1.2, 38% of patients) and  
High-Risk   (score> 1.2, 23% of patients). 
  
  
ANNEXURE 2 
HASFORD SCORING: 
The score is calculated using the following formula: 
 (0.6666 x age [0 when age < 50 years; 1 otherwise]) + (0.0420 x spleen 
size [cm]) + (0.0584 x blasts [%]) + (0.0413 x eosinophils [%]) + 
(0.2039 x basophils [0 when basophils < 3%; 1 otherwise]) + (1.0956 x 
platelet count [0 when platelets < 1500 x 109/L; 1 otherwise]) x 1000). 
 
Three risk groups were identified: 
Low-Risk   (score ≤ 780, 40.6% of patients),and  
Intermediate-Risk  (score 781 – 1480, 44.7% of patients) and  
High-Risk    (score ≥ 1481, 14.6% of patients). 
  
  
ANNEXURE 3 
 
 
EUTOS SCORING 
The EUTOS score is calculated as  
 (7 x basophil [%]) + (4 x spleen [cm]).  
 
Two risk groups were identified: 
Low-Risk    (score < 87, 79% of patients) and  
High-Risk    (score ≥ 87, 21% of patients) 
 
The 10EUTOS manuscript also provides the following formula for 
predicting the probability of no CCgR at 18 months:  
exp(−2.1007 + 0.0700 × basophils + 0.0402 × spleen size)/(1 + 
exp[−2.1007 + 0.0700 + basophils + 0.0402 × spleen size]).  
  
ANNEXURE 4 
CML response criteria 
European LeukemiaNet Response Criteria & Response Expectations 
Response Criteria Frequency of 
monitoring 
Complete Hematologic 
Response (CHR) 
Platelets < 450 x109/L, AND 
White cells < 10 x109/L, AND 
No circulating immature 
myeloid cells, AND 
< 5% basophils on differential, 
AND 
No palpable splenomegaly 
Every 2 weeks until 
CHR achieved and 
confirmed, then every 
3 months 
Minimal Cytogenetic 
Response 
(MinimalCyR) 
66 - 95% Ph+ cells* 
Every 6 months until 
CCyR achieved and 
confirmed, then 
annually 
Minor Cytogenetic 
Response (MinorCyR) 36 - 65% Ph+ cells* 
Every 6 months until 
CCyR achieved & 
confirmed, then 
annually 
Partial Cytogenetic 
Response (PCyR) 1 - 35% Ph+ cells* 
Every 6 months until 
CCyR achieved & 
confirmed, then 
annually 
Complete Cytogenetic 
Response (CCyR) No Ph+ cells* 
Every 6 months until 
CCyR achieved & 
confirmed, then 
annually 
Major Molecular 
Response (MMR) 
BCR-ABL ≤ 0.10% 
(international scale) 
Every 3 months 
(peripheral blood) 
Complete Molecular 
Response (CMR) 
BCR-ABL transcripts non-
quantifiable and non-detect-
able 
Every 3 months 
(peripheral blood) 
* At least 20 metaphases analysed on conventional cytogenetics of bone 
marrow aspirate  
 
  
Time (m) Optimal 
response 
Suboptimal 
response 
Treatment 
failure 
3 CHR plus at least MinorCyR 
No cytogenetic 
response < CHR 
6 At least PCyR < PCyR No cytogenetic 
response 
12 At least CCyR < CCyR < PCyR 
18 At least MMR < MMR < CCyR 
At any time 
Stable or 
improving 
MMR 
Additional cyto-
genetic abnorm-
alities in Ph+ 
cells, loss of 
MMR, mutation 
with a low level 
of insensitivity 
to imatinib 
Loss of CHR, 
loss of CCyR, 
mutation with a 
high level of in-
sensitivity to 
imatinib 
 
  
ANNEXURE 5 
 
MATERIALS REQUIRED FOR CYTOGENETIC STUDY 
 
1. Marrow Max 
2. Colcemid solution (10 µg/mL) 
3. Hypotonic solution: KCL (0.56%), distilled H2O (Mix 8:2) 
4. Fix: Methanol, Glacial Acetic Acid (Mix 3:1) 
5. Centrifuge tubes, 15 mL 
6. T-25 flasks 
7. Sterile transfer pipettes 
8. Nonsterile transfer pipettes 
9. Eppendorf pipette 
10. Incubator, 37ºC 
11. Centrifuge 
12. Microscope slides 
13. Oven, 90ºC 
14. Phase microscope (optional) 
15. Brightfield microscope 
  
MASTER CHART 
 
KEY TO MASTER CHART 
Symp  – Presenting Symptoms 
Tc d1  – Total WBC Count Day 1 
Tc 3 mon  – Total WBC Count 3 months 
Hb  – Haemoglobin 
Plt – Platelet Count  
SS  – Spleen Size  
Pp – Portal pressure 
PT  – Prothrombin Time 
APTT – Activated Partial Thromboplastin Time 
BMA  – Bonemarrow Aspiration 
F  – Fever 
P  – Abdominal Pain 
Fati  – Fatigue 
s.n  – Subcutaneous Nodules 
LN  – Lymphadenopathy 
Ph  – Standard t(9,22) 
M ACA 1 – 46xy,t(9,22)(q34;q11.2)[3]/48,idem,+8,inv(12),+21[22] 
M ACA 2  –  46xy,t(9,22)[8]/49xy,idem,+8,+19,t(9,22)[18] 
M ACA 3  –  46xy,t(9,22)[14]/ 47, idem, +der(22) t(9,22)[22] 
M ACA 4 –  46xx,-1,der(6)t(1,6) t(6,13), der(7)t(1,7), t(9,22), 
  del(10) +mar[23] /46XX[2]  
V,t  – 46xy,t(3,6,9,22)(p13;p21;q34;q11.2)[25] 
delY  – 46xy,t(9,22)(q34;q11.2)[3]/45x, idem, -y[22] 
210  – 210 KD Protein  
Gene  – Bcr Abl Quality 
Kar  – Karyotype 
P  –  Progression of Course 
G  –  No Progression of Course 
Acc  – Accelaraion Phase 
R/L                -       Renal / Liver Function Test 
